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Summary 
Conventional ex vivo dendritic cell (DC) vaccine strategies for the treatment of cancer are shown to be 
safe and to expand peptide-specific T cells in some patients. However, the feasibility and clinical 
efficacy are hampered by a laborious Good Manufacturing Practice (GMP) production and biological 
issues such as an impaired DC migration capacity. Targeting tumor-derived peptides to DC-associated 
endocytic receptors in vivo by antibody–antigen conjugates therefore represents a promising 
alternative. To induce a strong and sustained antigen-specific T cell response rather than tolerance, 
DC-targeting antibodies are commonly co-administered with toll-like receptor (TLR) agonists as 
adjuvants. In this context, peptide- or antibody-coupled TLR agonists have shown a higher vaccination 
efficacy and specificity compared to soluble adjuvants. To combine the advantages of in vivo DC 
vaccines with those of conjugated TLR agonists, we generated novel multifunctional antibody 
constructs (MACs) that simultaneously deliver antigens and TLR-activating adjuvants to DCs in a single 
molecule. 
The engineered MACs consist of an αCD40 single-chain variable fragment (scFv) or an Fc-silenced 
αCD40 IgG1 antibody fused to a CMV pp65-derived antigen including the immunodominant 
NLVPMVATV (CMVNLV) epitope for proof-of-principle studies. We showed that the αCD40 scFv bound 
agonistically to CD40 and highly upregulated maturation markers on monocyte-derived DCs (moDCs). 
The αCD40 IgG1, in contrast, exhibited low intrinsic agonistic activity. Upon binding, moDCs 
internalized αCD40 scFv and IgG1 antibodies into early endosomal compartments. As shown by DC–T 
cell co-cultures, moDCs incubated with CMV-coupled MACs cross-presented the processed CMVNLV 
peptide on the surface and induced a peptide-specific T cell activation and proliferation. A higher T 
cell response was obtained for the scFv format. In a next step, different TLR agonists were conjugated 
to MACs to compare their ability to stimulate DCs. The TLR4 agonist LPS and the TLR5 ligand flagellin 
further enhanced the DC maturation elicited by αCD40 scFv, but unexpectedly, TLR ligation did not 
affect or even diminished the T cell response. The TLR8 agonist ssRNA40 in combination with αCD40 
scFv led to a minor upregulation of DC maturation markers due to an insufficient uptake of the RNA, 
however, T cell proliferation was augmented. Notably, the combination of αCD40 IgG1 and flagellin in 
a single MAC molecule (αCD40.FlgCMV) matured DCs by specifically interacting with TLR5 and enhanced 
cross-presentation as well as the CMVNLV-specific T cell responses. Based on these results, 
αCD40.FlgCMV was classified as the most promising molecule to be further characterized. 
Finally, we could successfully confirm the functionality of the novel MAC format in a tumor setting by 
delivering the acute myeloid leukemia (AML)-specific mutated nucleophosmin (mNPM1)-derived 
neoantigen CLAVEEVSL (mNPM1CLA) to DCs. This is the first study to investigate mNPM1 in a DC 
vaccination context and to fuse a neoantigen to a DC-targeting antibody. DCs loaded with mNPM1-
coupled αCD40 scFv and αCD40 IgG1 were able to induce efficient mNPM1CLA-directed T cell 
responses. Again, fusing flagellin to αCD40 IgG1 revealed a beneficial effect on DC maturation and 
cross-presentation, which demonstrates a high therapeutic potential for αCD40.FlgmNPM1. 
The fusion of flagellin to an antigen-conjugated αCD40 IgG1 was identified as the most promising 
strategy to co-deliver a peptide and a TLR-stimulating signal to DCs that activates DCs and thereby 
boosts peptide-specific T cell responses. The herein described data prove the functionality of flagellin 
fusion molecules in vitro. They lay the foundation for the therapeutically relevant αCD40.FlgmNPM1 MAC 
to become a promising option for treating AML in the future, especially upon combination with other 
immunotherapeutic approaches such as adoptive T cell therapy or immune checkpoint blockade.  
Zusammenfassung 
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Zusammenfassung 
Konventionelle ex vivo Vakzinierungsstrategien mit dendritischen Zellen (DZs) zur Behandlung von 
Krebs sind erwiesenermaßen sicher und konnten Peptid-spezifische T-Zellen in einigen Patienten 
expandieren. Jedoch sind die Durchführbarkeit und die klinische Wirksamkeit durch die aufwändige 
GMP-Produktion der Vakzine sowie durch biologische Probleme, wie die beeinträchtigte 
Migrationsfähigkeit der DZs, vermindert. Der in vivo Antigen-Transfer zu endozytischen 
Oberflächenrezeptoren auf DZs in Form von Antikörper-Antigen-Konjugaten stellt eine 
vielversprechende Alternative dar. Um eine starke und langanhaltende Antigen-spezifische T-Zell-
Antwort auszulösen und T-Zell-Toleranz zu verhindern, werden DZ-bindende Antikörper für 
gewöhnlich mit Toll-like Rezeptor (TLR) Agonisten als Adjuvanzien verabreicht. In diesem 
Zusammenhang wurde bereits gezeigt, dass Peptid- oder Antikörper-gekoppelte TLR Agonisten 
Vorteile bezüglich der Vakzinierungseffizienz und -spezifität im Vergleich zu löslichen Adjuvanzien 
aufweisen. Um die potentiellen Vorteile der in vivo DZ-Vakzinierung mit denen der gekoppelten TLR 
Agonisten zu kombinieren, wurden in dieser Arbeit multifunktionelle Antikörperkonstrukte 
(multifunctional antibody constructs, MACs) generiert, die den zielgerichteten Transport von 
Antigenen und TLR-aktivierenden Adjuvanzien zu DZs in einem Molekül kombinieren. 
Die Antikörperkonstrukte bestehen aus einem αCD40 single-chain variable fragment (scFv) oder 
einem αCD40 IgG1 mit mutiertem Fc-Teil, an die ein CMV pp65-spezifisches Antigen fusioniert ist, das 
das immundominante NLVPMVATV (CMVNLV) Epitop enthält. Wir konnten zeigen, dass der αCD40 scFv 
agonistisch an CD40 band und in hohem Maße Maturierungsmarker auf Monozyten-abgeleiteten DZs 
(moDZs) hochregulierte. Im Vergleich dazu wies der αCD40 IgG1 nur eine geringe intrinsische 
agonistische Aktivität auf. Nach Bindung internalisierten moDZs die αCD40 scFv und IgG1 Antikörper 
in frühe Endosomen. In DZ/T-Zell-Kokulturen wurde gezeigt, dass moDZs, die mit den αCD40 
Konstrukten beladen wurden, das prozessierte CMVNLV Peptid an der Oberfläche kreuzpräsentierten 
und eine Peptid-spezifische T-Zell-Aktivierung und -Proliferation induzierten, wobei das scFv Format 
eine höhere Antwort auslöste. Anschließend wurden verschiedene TLR Agonisten an die Antikörper 
gekoppelt und anhand ihres stimulatorischen Potentials verglichen. Der TLR4 Agonist LPS und der TLR5 
Ligand Flagellin verstärkten die durch αCD40 scFv hervorgerufene DZ-Maturierung, aber 
unerwarteterweise beeinflusste die TLR Ligation die T-Zell-Antwort nicht oder reduzierte sie sogar. Die 
Kopplung von ssRNA40 an αCD40 scFv führte nur zu einer geringen Hochregulation von 
Maturierungsmarkern aufgrund von einer unzureichenden Aufnahme der RNA, jedoch erhöhte die 
ssRNA40 die Aktivierung und Proliferation CMVNLV-spezifischer T-Zellen. Bemerkenswerterweise 
konnte die Fusion von Flagellin an αCD40 IgG1 (αCD40.FlgCMV) sowohl die DZs durch eine spezifische 
Interaktion mit TLR5 maturieren, aber auch die Kreuzpräsentation von Peptiden und die CMVNLV-
spezifische T-Zell-Antwort verstärken. Folglich wurde dieses Molekül als das Vielversprechendste 
eingestuft, das weiter charakterisiert werden sollte. 
In einem nächsten Schritt konnten wir die Funktionalität des Molekülformats auch im Tumorsetting 
bestätigen, indem wir die virale Antigendomäne gegen ein Akute Myeloische Leukämie (AML)-
spezifisches Neoantigen CLAVEEVSL (mNPM1CLA) austauschten, das vom mutierten Nukleophosmin 
(mNPM1) Protein abstammt. Dies ist die erste Studie, die den Einsatz von mNPM1 im Kontext einer 
DZ-Vakzinierung beschreibt und ein Neoantigen an einen DZ-bindenden Antikörper fusioniert. DZs, die 
mit mNPM1-gekoppeltem αCD40 scFv und IgG1 beladen wurden, konnten eine effiziente mNPM1CLA-
spezifische T-Zell-Antwort auslösen. Die Fusion von Flagellin an αCD40mNPM1 zeigte abermals einen 
vorteilhaften Effekt auf DZ-Maturierung und Peptid-Kreuzpräsentation, welcher für ein hohes 
therapeutisches Potential von αCD40.FlgmNPM1 spricht. 
Zusammenfassung 
3 
 
In dieser Arbeit wurde die Fusion von Flagellin an einen Antigen-gekoppelten αCD40 IgG1 Antikörper 
als die aussichtsvollste Methode identifiziert, um sowohl ein Peptid als auch ein TLR-stimulierendes 
Signal zu DZs zu transferieren und effiziente Peptid-spezifische T-Zell-Antworten zu induzieren. Diese 
initialen Experimente weisen die Funktionalität von Flagellin-Fusionsmolekülen in vitro nach. Sie legen 
außerdem den Grundstein für das therapeutisch relevante αCD40.FlgmNPM1 Molekül, um in der Zukunft 
eine Behandlungsstrategie der AML zu werden, vor allem in Kombination mit weiteren 
Immuntherapien wie dem adoptiven T-Zell-Transfer oder der Immuncheckpoint Blockade. 
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1. Introduction 
1.1. Dendritic cells  
1.1.1. DC biology 
Dendritic cells (DCs) are antigen-presenting cells (APCs) that are characterized by a unique capacity to 
orchestrate T cell-mediated immune responses. The first subtype of cells with a dendritic phenotype 
described were Langerhans Cells (LCs) in the skin in 1868, named after his explorer Paul Langerhans.1 
At that time, the distinct function of those cells was not even known. More than one century later, 
Ralph Steinman and Zanvil A. Cohn shed light upon the cell function by discovering the antigen 
presentation by DCs.2  Steinman’s later finding that DCs play a crucial rule in the immune system by 
bridging innate and adaptive immune responses changed the field of immunology.3, 4 It finally 
connected the work of Paul Ehrlich and Ilya Metchnikoff from the early 20th century, which was even 
honored with the Nobel Prize in Physiology or Medicine in 2011.5 
DCs originate from CD34+ hematopoietic stem cells (HSCs) in the bone marrow and arise from the 
lympho-myeloid hematopoiesis. They are a heterogeneous population of different subtypes that differ 
in their function, development as well as their regulation of T cell function.6 Under steady state, the 
generation of most DC subsets is controlled by the cytokine Fms-like tyrosine kinase 3 ligand (Flt3L). 
In addition, during inflammation and infection, granulocyte-macrophage colony-stimulating factor 
(GM-CSF) mobilizes and stimulates the production of monocyte-derived DCs.7 In the classical DC life 
cycle (Figure 1), DCs circulate as precursors through the blood stream. Immature DCs are specialized 
in antigen capturing, processing and presentation and reside in the peripheral tissues at sites of 
potential antigen entry, for example in the skin and internal or mucosal surfaces. Once they are 
activated by inflammatory and pathogen-derived signals (pathogen-associated molecular patterns 
(PAMPs)) via patter recognition receptors (PRRs), they migrate into the draining lymph nodes or 
lymphoid tissues. There they get in contact with naïve T cells that are in search for their cognate 
antigen, but have never been exposed to antigen before. Productive activation of naïve T cells by DCs 
results in their clonal expansion and differentiation into CD4+ or CD8+ effector and memory T cells, 
thereby activating effective T cell-specific immune responses.6-8 
 
Figure 1. Classical DC life cycle (adapted from Lutz et al.).9 
 
Immature DC Mature DC
Endocytosis low
MHC high
Costimulation high
Endocytosis high
MHC low
Costimulation neg/low
Antigen uptake T cell activation
Tissues Lymph nodeMicrobial or 
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1.1.2. DC subtypes 
DCs represent just a small population of leukocytes, but they are comprised of various subsets, each 
of them with an individual combination of surface markers, functions, origin and location (Figure 2). It 
is commonly accepted that DCs are divided into three major subsets that are derived from a common 
precursor: plasmocytoid DCs (pDCs), myeloid/conventional DC1 (cDC1) and myeloid/conventional DC2 
(cDC2).10 Each group develops under the control of different levels of the key transcription factors, 
most prominently of interferon regulatory factors 4 and 8 (IRF4 and IRF8).11 Besides the 
aforementioned major subsets, there are other parts of the DC family that are derived from different 
precursors and share similarities with macrophages or monocytes, respectively.10, 11 Among those are 
LCs, a unique population of mononuclear phagocytes restricted to the epidermal skin layer, and 
monocyte-derived DCs (moDCs) that differentiate from monocytes especially during inflammation.1, 
12 The different DC subtypes will be further characterized in the following sections. 
 
Figure 2. Major subsets of DCs (adapted from Collin et al. and Lutz et al.).12, 13 
 
In humans, cDC1 are marked by cluster of differentiation (CD)141 expression and cDC2 by CD1c 
expression.14, 15 cDC1 efficiently cross-present antigens to CD8+ T cells and produce high levels of 
interleukin (IL-)12p70, thus promoting cytotoxic T cells and T helper (Th) 1 cells.16-19 In contrast, cDC2 
support Th1, Th2 and Th17 polarization by being superior in presenting antigens on MHC class II.17, 20 
However, appropriately activated cDC2 cells are also able to secrete high amounts of IL-12 and recent 
studies suggested that both cross-presentation to CD8+ T cells and Th1 activation are less restricted to 
the cDC1 lineage in humans compared to what is known in mice.19, 21 
pDCs participate in the first line defense against viral infections. They act as innate effector cells, which 
initiate type I interferon (IFN)-induced antiviral responses in adjacent cells and recruit cytotoxic 
natural killer (NK) cells.22 Resting and non-stimulated pDCs are weak APCs and do not prime naïve T 
cells in contrast to cDCs. However, they can acquire the capacity to present antigens after activation. 
This also confers pDCs the ability to generate efficient effector CD8+ T cell responses against 
exogenous antigens.23 In addition, by producing cytokines and chemokines pDCs modulate T cell 
responses elicited by cDCs.22  
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There has been the discussion in the field whether LCs and moDCs are considered to belong to the DC 
family or not. They exhibit a distinct gene expression profile that is more similar to that of 
macrophages or monocytes rather than DCs.13, 24 However, both also share common features with 
cDCs. The epidermally resident LCs migrate to skin-draining lymph nodes, have a high functional cross-
presentation capacity and MHC class I-related gene expression and a low CD11c expression, what they 
have in common with cDC1 cells.25 However, they also share a variety of surface markers, such as 
FcεR1 and CD39, which cDC2.26 MoDCs, also termed “inflammatory DCs”, are induced in vivo under 
inflammatory and infectious conditions that recruit monocytes into tissues. There, they develop into 
DCs initiating T cell priming in the draining lymph nodes.11, 14 MoDCs can be also differentiated from 
monocytes in vitro in the presence of GM-CSF and IL-4.27, 28 These artificially generated moDCs could 
serve as a tool for therapeutic strategies and to study DC biology as they resemble a cDC-like cell type 
in vitro. Both in vivo naturally occurring and in vitro generated moDCs rely on factors, such as GM-CSF, 
M-CSF and IL-37, however, their precise roles are not fully understood.13 
 
1.1.3. Antigen processing and presentation  
In general, DCs in the periphery can present antigens on major histocompatibility complex (MHC) class 
II or I leading to the activation of CD4+ or CD8+ T cells, respectively. For the processing and presentation 
of endogenous and exogenous antigens, different mechanisms have been described. In DCs, cytosolic 
self- or virus-derived endogenous antigens are degraded by proteasome degradation into smaller 
peptides and transferred to the endoplasmatic reticulum (ER) by transporters associated with antigen 
processing (TAP). Subsequently, peptides are loaded within the ER on MHC class I molecules, which 
are then rapidly transferred through the Golgi apparatus to the plasma membrane.29, 30 There, 
peptide-MHC I complexes interact with CD8+ T cells, thereby allowing the immune system to identify 
and eliminate virally infected or transformed cancer cells that either display modified self or foreign 
proteins.31 MHC II molecules, in contrast, associate with peptides derived from exogenous antigens 
that come from pathogens or abnormal cells. DCs constitutively scan peripheral areas for those cells 
or particles that are internalized by clathrin-mediated endocytosis, phagocytosis, micropinocytosis or 
trogocytosis into the endosomes and lysosomes.32 In this compartments, exogenous antigens are 
processed into peptide fragments and loaded on MHC class II receptors. After transport to the surface, 
peptides bound to MHC II molecules are presented to CD4+ T cells.30, 33  
In addition to the classical MHC class I and II pathway, DCs also exhibit the special feature to present 
exogenous proteins on their surface on MHC I molecules, a process called cross-presentation.34 Two 
major pathways of antigen cross-presentation can be distinguished (Figure 3). In the vacuolar 
pathway, antigen processing, degradation by lysosomal proteases and loading on MHC I molecules 
occurs within the endo/lysosomal compartment.35 In the endosome-to-cytosol pathway, internalized 
antigens need to be transported from the endosomal compartment into the cytosol, where they are 
degraded by the proteasome.36 Afterwards, derived peptides are shuttled by TAP transporters into 
the ER or back into the antigen-containing endosomes, where they are loaded into MHC molecules 
and transported to the plasma membrane.37, 38 Subsequently, interaction with antigen-specific T cells 
takes place.  
Conclusively, this process of cross-presentation is particularly important not only in vivo during 
infectious and tumor conditions but also for therapeutic approaches, to transform naïve CD8+ T cells 
into effector cytotoxic T lymphocytes (CTLs) and therefore eliminate harmful target cells.39, 40 
Moreover, the ability to cross-present is not a feature of specialized DC subsets, but is rather tuned 
by and dependent on several factors, such as DC location and DC maturation status.41  
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Figure 3. Pathways of peptide cross-presentation via MHC I.31 
 
1.1.4. “Three-signal” hypothesis of T cell activation 
The presentation of peptides on the DC surface on MHC I or II molecules as peptide–MHC complexes 
(p–MHC) is followed by interaction with specific T cell receptors (TCRs) on CD8+ or CD4+ T cells, 
respectively. If CD8+ T cells are activated, they differentiate into CTLs that can give rise to both effector 
and memory cells.42 CD4+ T cells, also called Th cells, can either stimulate cytotoxic responses (Th1, 
Th17), antibody responses (Th2) or inhibit immune responses (regulatory T cells, Tregs).43 The fate of 
differentiation will strongly depend on the type of cytokines and chemokines present during DC 
contact. 
It is hypothesized that three signals are necessary to effectively activate T cells (Figure 4). The initial 
engagement via p-MHC and TCR, that forms the immunological synapse between DCs and T cells, 
confers “signal 1” of T cell activation, which is also commonly termed “T cell priming”.43 Triggering of 
the TCR alone is insufficient und usually leads to T cell anergy as indicated by a limited T cell expansion 
followed by unresponsiveness after reencountering antigen.44, 45 To activate T cells, a second signal 
called “co-stimulation” is necessary that is delivered by the interaction of T cell surface receptors with 
their ligands on the DC plasma membrane. Two classes of co-stimulatory molecules exist on the 
surface of T cells. Those include the immunoglobulin (Ig) superfamily members, such as CD28, that 
interact with several members of the B7 family (CD80, CD86) on the DC.46-48 The other class consists 
of members of the tumor necrosis factor (TNF) receptor superfamily (CD27, CD40) that bind to 
membrane-attached proteins of the TNF superfamily.46, 49 Especially the engagement of CD28 is 
important, as it alters the threshold level of TLR ligation required for activation, reduces the time 
needed to stimulate naïve T cells and enhances the magnitude of T cell responses.6 Signal 1 and 2 may 
already activate T cells. However, an additional signal has to be provided which will polarise T cell 
differentiation. Therefore, “signal 3” is delivered by DCs via the production of pro- or anti-
inflammatory cytokines to regulate and control the type and quality of triggered T cell responses. One 
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well-studied third signal agent is IL-12p70 that is involved in the induction of Th1 and CTLs. Both are 
essential for efficient pathogen, but also tumor rejection.50, 51 Type I interferons (IFN) contribute 
similarly to Th1 and CTL expansion and differentiation in vitro and in vivo.52, 53 In addition, the secretion 
of IL-4 drives Th2 differentiation and the combination of IL-6 and TGF-β together with IL-23 promote 
Th17 responses.54, 55 Of note is that also NK cells and B cells respond to DC-derived cytokines, especially 
IL-12p70, indirectly promoting adaptive immunity.56, 57 
 
Figure 4. “Three-signal hypothesis” of T cell activation. 
 
Signal 2 and 3 are delivered by the maturation of DCs. The latter is stimulated by inflammatory and 
pathogen-derived signals, more exactly the PAMPs recognized via PRRs. Upon activation, immature 
DCs are matured resulting in the expression of co-stimulatory molecules, such as CD80, CD83, CD86 
and CD40, secretion of cytokines and migration to lymphoid organs where DCs can interact with 
antigen-specific T cells.58 As DCs also process and present autoantigens, the contribution of signal 2 
and 3 is particularly important for the overall immune response to prevent autoimmunity and to 
establish immunological tolerance in the absence of a pathogen-derived signal.43 In this context, not 
only the absence of positive co-stimulation triggered by DC maturation, but also the presence of 
negative co-stimulation and the secretion of inhibitory cytokines might alter the immune response. 
Exemplarily, CD80/CD86 can engage inhibitory receptors on T cells such as cytotoxic T-lymphocyte 
antigen 4 (CTLA4) leading to anergic T cells or Tregs.59  
Collectively, the complex interplay of activating and inhibiting factors determines the fate of a T cell 
response after encountering an antigen-presenting DC. 
 
1.2. DC-based cancer vaccines 
1.2.1. General concept 
Reprogramming of the immune system against cancer by immunotherapeutic approaches has shown 
clinical promise in recent decades. In this context, therapeutic cancer vaccines are developed including 
virus vector vaccines, molecular vaccines comprised of peptide, DNA or RNA vaccines, and cellular 
vaccines.60 Among those, DC-based cancer vaccines are intensely investigated. DCs represent a 
powerful tool for cancer immunotherapy due to their high capacity to take up and present antigens, 
for example through cross-presentation. Besides direct antigen presentation, additional DC-intrinsic 
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properties are relevant for immunotherapy, such as the capacity for migration between lymphoid and 
non-lymphoid tissues as well as the modulation of cytokine and chemokine gradients to control 
inflammation and lymphocyte homing. All those factors are presumably important to promote 
systemic and long-lasting antitumor effects.61 
In many tumors, immune responses are ineffective as the tumor lacks immunogenicity and often 
creates an immunosuppressive environment.62, 63 The tumor microenvironment promotes exhaustion 
of CD8+ T cells directly or hampers the recruitment of cDC1 cells, thereby inhibiting priming and 
accumulation of tumor-infiltrating T cells.64, 65 DC vaccines aim to reverse the ineffective immune 
responses and the ignorance of the immune system to malignant cells. To achieve this, DCs are 
stimulated with danger signals and loaded with tumor-specific antigens on MHC molecules. By 
activating antigen-specific T cells, antigen-bearing cancer cells are supposed to be selectively 
eliminated.66 Ideally, therapeutic vaccines should both prime naïve antigen-specific CD8+ T cells to 
generate CTLs, but also modulate existing memory T cells and induce the transition from chronically 
activated non-protective CD8+ T cells to healthy CD8+ T cells. These, in turn, generate CTLs that reject 
cancer but also provide long-lived memory CD8+ T cells to prevent relapse.67 In addition, the activation 
of CD4+ T cells by the vaccine has shown therapeutic benefits by producing cytokines to support CD8+ 
T cell proliferation and differentiation.68 
Thus, the prerequisites of all DC-based cancer vaccines include a large source of DCs that exhibit a high 
cross-presenting capacity and are sufficiently matured to induce an efficient and sustained T cell 
response. Two different vaccination strategies have been developed and already implemented as part 
of clinical trials. In one approach, DCs are generated and loaded with the desired antigen ex vivo 
followed by re-infusion into the patient. Alternatively, antigens are targeted to DCs in vivo by fusing 
or complexing it with antibodies or other DC-targeting vectors.69  
 
1.2.2.  Target selection and antigen source 
The selection of an appropriate target represents one of the most important steps towards vaccine 
development. Targets for tumor vaccines can be divided into two classes: tumor-associated antigens 
(TAAs) and tumor-specific antigens (TSAs) (Figure 5).60  
 
Figure 5. Tumor-associated vs. tumor-specific antigens (adapted from Hollingsworth et al.).60 
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To date, most cancer vaccines target TAAs. These are self-antigens that are either preferentially or 
abnormally expressed on tumor cells, but may be present at some level also on normal cells. T cells 
that bind with high affinity to TAAs are typically deleted from the immune repertoire by central and 
peripheral tolerance mechanisms. Thus, a cancer vaccine targeting these antigens must be potent 
enough to “break tolerance” and to stimulate the low affinity or rare TAA-reactive T cells that haven’t 
been eliminated.70 This seems to be difficult to achieve, as several clinical trials targeting TAAs have 
shown that long-term therapeutic effects are often lacking.71 As a second challenge, expression of 
TAAs on normal cells may lead to on-target off-tumor toxicity. This hasn’t been described for cancer 
vaccines so far due to lacking potency, but toxicities are a common observation for other TAA-targeted 
therapies.60 
In contrast to TAAs, TSAs are truly tumor-specific and are recognized by the immune system as foreign. 
As such, high-affinity T cells may be present and strongly activated by these antigens. TSAs can be 
either antigens expressed by oncoviruses, for example human papilloma virus (HPV) responsible for 
cervical cancer, or antigens encoded by tumor-specific mutations, the so called neoantigens. Oncoviral 
antigens are commonly expressed in many patients and so are some neoantigens that are derived 
from hotspot mutations occurring in multiple cancer patients. However, the majority of neoantigens 
are unique to individual patient’s tumor (private neoantigens) and require the generation of 
personalized therapy.60 Early clinical trial results testing personalized neoantigen vaccines, for 
example in melanoma patients, are very promising and state reasons to further develop these 
therapies.72-76 The generation of “off-the-shelf” vaccines employing neoantigens that are shared 
between patients is still in the early stages. As those neoantigens are quite rare, clinical results are 
missing even if a high therapeutic potential can be expected.77, 78 
The DC vaccine can consist of either a single MHC I-restricted epitope as target source or several 
epitopes.79 Loading of DCs with epitopes derived from multiple antigenic proteins is suggested to be 
beneficial over single antigen vaccination. This offers a better chance of recognition and less chance 
of escape by epitope mutations.80, 81 In this context, also a combination of MHC class I and II epitopes, 
for example in so-called long synthetic peptides (LSPs), might be applied. Due to the significant 
contribution of CD4+ T cells to the overall immune response, vaccination with LSPs has been shown to 
generate robust and long-term CD4+ and CD8+ T cell responses.82 Selected antigen candidates are 
always specific for an individual human leukocyte antigen (HLA) type, which makes it hard to produce 
“off-the-shelf” vaccines. To overcome this problem, overlapping peptide libraries, tumor cell lysates 
or nucleic acids encoding tumor antigens can be used to cover all possible tumor epitopes without 
HLA restriction.85, 86 Even if vaccination with multiple peptides and different epitopes has shown 
promising results, a lot of clinical trials investigate single antigen vaccination. These are also able to 
induce clinical responses and their efficacy can be enhanced by a phenomenon called “epitope 
spreading”. As a vaccine that targets just one antigen can result in tumor cell lysis by specific T cells, 
new tumor antigens are released, thereby broadening and spreading the response from one to 
multiple antigens.83, 84 
 
1.2.3.  Ex vivo DC vaccination 
The process of ex vivo DC vaccination involves the generation of patient-derived autologous DCs, that 
are matured with danger signals, loaded with selected candidate peptides and re-infused to induce a 
tumor-specific T cell response (Figure 6). Pioneering work of Inaba, Steinman and colleagues from 
1992 ushered the era of ex vivo DC vaccines as they demonstrated that mouse DCs can be cultured ex 
vivo from bone marrow precursors.85  
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The generation of sufficient numbers of human DCs for vaccination purposes was one major challenge, 
as DCs comprise <1% of peripheral blood mononuclear cells (PBMCs).11 Most commonly moDCs are 
used that can be generated ex vivo in large numbers from purified monocytes that were cultured in 
presence of GM-CSF and IL-4.27 These were first used as a source for therapeutic DCs to treat 
lymphoma patients over two decades ago.86 Recent work of Sharma and colleagues found out that 
monocytes cultured with GM-CSF, IL-6 and IFN-γ give rise to a newly described mo-cDC1 population 
that share even more similarities with cDC1s.87 Additionally, cDCs and pDCs can be generated from 
CD34+ hematopoietic stem cells using Flt3L.81, 88 The phenotype, function and ability to induce T cell 
responses by in vitro generated DCs is highly dependent on the culture methods but also the cytokines 
and growth factors used for differentiation.89 Even different techniques for monocyte isolation are 
shown to influence the antitumor immunogenicity and cytokine production of generated moDCs.90, 91 
 
Figure 6. Ex vivo DC vaccination (adapted from Tacken et al.).92 
 
The generated DC-like cells with an immature phenotype need to be matured prior to administration. 
When vaccinating in the absence of adjuvants as proper maturation factors, tolerance has been 
observed.93, 94 Only DCs matured by danger signals are immunological competent, able to induce an 
efficient T cell response and exhibit a high migratory capacity towards draining lymph nodes. Various 
maturation cocktails have been used in the clinic to stimulate moDCs. These generally consist of 
different ligands for PRRs and cytokines, often in combination with co-stimulatory proteins such as 
CD40 ligand (CD40L or CD154).61  
Antigen loading occurs at either the immature or mature DC stage. To load DCs with selected tumor 
antigens, different techniques are available. Antigens may be supplied by pulsing or electroporation 
with single peptides or tumor cell lysates, by transfection with an antigen-encoding RNA or DNA or by 
transduction using viral vectors that express tumor antigens.95-100  
DCs also need to reach the lymph nodes in vivo in order to present antigen to cognate antigen-specific 
T cells and to induce an immune response. DC-trafficking to lymph nodes is not only dependent on 
the DC maturation state, but might be also influenced by the injection routes and strategy. Different 
vaccine administration routes were tested, ranging from intra-dermal (i.d.), intra-nodal (i.n.) to intra-
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tumoral injection. However, the data didn’t show clear a benefit of any administration route that was 
consistent among clinical trials. Therefore, the superior site of injection is still unknown.11 
Numerous clinical trials have established the safety and efficiency of moDC vaccines.101 However, this 
approach is quite laborious and expensive, as the DCs have to be generated for each patient 
individually. Therefore, protocols need to be optimized and accelerated. Most protocols for the 
generation of clinical-grade moDCs require 7 days of cell culture.102 New methods have been 
developed to ensures a less time- and labor-intensive production of DCs within just 2-3 days. The 
resulting DCs had a mature phenotype and were equally potent in inducing antigen-specific T cell 
responses compared to DCs generated according to the long protocol.103, 104 As an example, moDCs 
generated in this thesis for in vitro studies were based on a three-day protocol developed before. This 
starts with monocyte differentiation into immature DCs for 48 h with GM-CSF and IL-4 followed by DC 
maturation for 24 h with a TLR7/8 agonist-containing cytokine cocktail for the generation of Th1-
polarizing DCs.105, 106 
 
1.2.4.  In vivo DC vaccination 
More recently, in vivo loading of DCs is being exploited as an alternative approach to ex vivo DC 
vaccination as targeting DCs in vivo with antigens and adjuvants may simplify vaccination and produce 
more physiological DC maturation.80, 92 The vaccine can be produced on a larger scale since it is 
applicable to a larger patient cohort. Steinman and his colleague Nussenzweig were the first to 
demonstrate the principle of targeting antigens to DCs in vivo through coupling of antigens to 
antibodies specific for DC surface receptors.107-109 After binding its cognate receptor, the antibody is 
internalized into intracellular compartments, the attached peptide is processed and (cross-)presented 
on MHC I or II molecules to activate peptide-specific CD4+ or CD8+ T cells (Figure 7). 
 
Figure 7. In vivo DC vaccination. 
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The most commonly used CLRs for antibody-targeted approaches are the mannose receptor (MR),  
205 kD membrane protein (Dec205), Dectin 1 and 2, dendritic cell natural killer lectin group receptor-
1 (DNGR-1 or Clec9A) and DC-specific ICAM-3 grabbing non-integrin (DC-SIGN).111 Some CLRs serve as 
phagocytic receptors only, whereas other CLRs activate a signaling cascade via immune-receptor 
tyrosin-based activation motifs (ITAMs) to initiate immune responses.112 Further CLRs contain 
immune-receptor tyrosine based inhibitory motifs (ITIMs) that inhibit cellular activation to prevent 
uncontrolled immune responses.113 Hence, various CLRs differ in the ability to induce an immune 
response in addition to its endocytic function. In addition to targeting CLRs, antibodies against Fc 
receptors (FcR) and CD40 can also be used. The latter exhibits an exceptional position among DC 
receptors targeted for vaccination approaches.111 CD40 not only serves as an endocytic receptor, but 
also exhibits intrinsic activating function after cross-linking of CD40 on the DC surface either by 
interacting with CD40L on activated T cells or by agonistic antibody constructs.114 
All endocytic receptors have differential levels of expression, internalization patterns and downstream 
trafficking routes. The amount of internalized antigen and receptor expression level was shown not to 
correlate with the antigen presentation level in previous studies.115 Exemplarily, Chatterjee et al. 
described that an anti-MR (αMR) antibody was more efficiently accumulated intracellularly than 
αCD40 or αDec205. However, CD40 was the best receptor to target to induce antigen cross-
presentation, which was not mediated by αCD40-dependent DC activation. They suggested that rather 
its relatively poor uptake or intra-endosomal degradation in early endosomes is beneficial over a high 
uptake and trafficking to late endosomes as seen for MR- and Dec205-targeting.116 The used antibody 
might also determine which DC subtype, but also which other cells to be targeted. Dec205 is expressed 
at high levels on moDCs and monocytes, at intermediate levels by B cells and at low levels on NK cells, 
T cells and pDCs.117 CD40, in turn, is expressed not only on all DC subsets, B cells, monocytes and 
macrophages, but also by hematopoietic progenitors, fibroblasts, endothelial and epithelial cells.118-
120 As PRRs are also differentially expressed on DC subtypes and cellular compartments, the adjuvant 
and DC-targeting antibody should be selected well-orchestrated. This ensures that PRR ligation and 
antigen loading is found on the same DC and in the correct cellular compartments.41 
DCs can be targeted by different antibody formats including an IgG1-based conventional antibody, Fab 
and F(ab’)2 fragments or single-chain variable fragments (scFv) (Figure 8). The Fc domain of IgG1 
antibodies commonly conjugates them to activating FcγR on immune effector cells. This triggers 
immune responses, such as antibody-dependent cellular cytotoxicity (ADCC), phagocytosis (ADCP) or 
complement-dependent cytotoxicity (CDC). Engagement of inhibitory FcγR dampens immune 
responses.121 For DC-based vaccines, using scFv offers some advantages over the IgG format. Due to 
smaller size, scFv penetrate the tissue much better.122 Since they lack an Fc domain, they do not bind 
to FcRs and hence do not induce unwanted effector functions and provide specific antigen delivery by 
reducing non-specific uptake of antigen by other effector cells.123 As a drawback to antibody 
constructs with bigger size, scFv have a shorter half-life due to a fast renal clearance.122 Therefore, 
silencing Fc-mediated functions by introducing PGLALA (P329G, L234A and L235A) mutations would 
represent an alternative approach to using Fab- or scFv-based molecules.124  
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Figure 8. Different antibody formats to be used to target DCs in vivo (adapted from De Groof et al.).125 
 
In accordance to the “three-signal” hypothesis of T cell activation and similar to ex vivo DC vaccination, 
also in vivo vaccines need co-stimulation and DC maturation besides antigen loading. Therefore, most 
of antibody–antigen conjugates are co-administered with adjuvants, which are commonly ligands for 
PRRs. This is particularly necessary for targeting for example Dec205, as in the absence of an adjuvant 
antigen-specific tolerance is induced that could serve as a treatment against autoimmune diseases.108, 
126 As agonistic αCD40 and some αCLR antibodies already elicit co-stimulatory functions, DC-targeting 
and adjuvant are combined in one molecule.127, 128 Still, the addition of an additional maturating agent 
might show synergistic effects. In line with this, the combination of αCD40 with other PRR ligands 
further boosted the immune response and synergized to stimulate CD8+ T cells in response to peptide 
and DC vaccines in previous studies.129-131 Aside from the co-administration of the DC vaccine and the 
adjuvant, DC-activating factors can also be directly targeted to the antibody and the DC by genetic 
fusion or covalent coupling. This is expected to reduce off-target effects of soluble adjuvants by 
activating only DCs presenting the desired antigen.132, 133 More importantly, it is also shown to enhance 
therapeutic efficacy.133, 134 
Conclusively, the DC-targeting antibody in combination with the adjuvant selected for the in vivo DC 
vaccination approach determines the fate of loaded DCs and therefore the specificity and efficiency 
of the induced immune response. As pre-clinical evaluations showed promising outcomes and 
encouraged further optimization of in vivo DC vaccination strategies, the first clinical trials are 
ongoing.135, 136 
 
1.3. Pattern recognition receptors  
1.3.1. Pattern recognition receptor biology  
The innate immune system serves as the body’s first line of defense and is the major contributor to 
acute inflammation induced by microbial infection and tissue damage.137, 138 Innate immunity is also 
important for the activation of acquired immunity. The innate immune system is essentially made up 
of barriers to repel pathogens, including skin, mucosa and secretions.139 Immune effector cells are also 
involved that encompass phagocytic cells, epithelial and endothelial cells, NK cells, innate lymphoid 
cells and platelets. Phagocytic cells consist of granulocytes, monocytes, macrophages and DCs. The 
majority of this cells expresses PRRs on the cell surface that recognize not only PAMPs but also cellular 
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damage-associated molecular patterns (DAMPs) derived from the host cell. All PRRs share common 
characteristics, such as their constitutive expression in the host and the detection of pathogen 
regardless of their life-cycle stage. They are germline encoded, nonclonal, expressed on either all cells 
or a given type and independent of immunologic memory. Depending on the PRR subtype and the 
nature of PAMP recognized, distinct signaling pathways and antipathogenic responses are induced, 
but the basic machineries of PAMP recognition are highly conserved among species.137 
PRRs include toll-like receptors (TLR), Nod-like receptors (NLR), CLRs, RIG-I-like receptors (RLR), AIM2-
like receptors (ALR) and various DNA-recognizing receptors, such as cyclic GMP-AMP synthase (cGAS), 
DNA-dependent activator of IFN-regulatory factors (DAI), interferon-γ inducible protein 16 (IFI16), 
DEAD box polypeptide 41 (DDX41) and stimulator of interferon genes (STING).137, 139-141 While TLRs and 
CLRs are transmembrane proteins found in the plasma membrane, RLR, ALR, NLR and DNA receptors 
are located in intracellular compartments, namely the endosome or cytosol.142 PRRs use specific 
adapter proteins to recruit various protein kinases, ubiquitin ligases and transcription factors to the 
signaling complex. Subsequently, activated transcription factors translocate to the nucleus and induce 
transcriptions of genes encoding inflammatory cytokines, IFN, chemokines and antimicrobial 
proteins.142, 143 The inflammatory response is orchestrated by proinflammatory cytokines such as TNF, 
IL-1 and IL-6. These are pleiotropic proteins that regulate cell death and apoptosis of inflammatory 
tissues and recruit immune cells to inflamed tissues thereby stimulating adaptive immunity.142, 144  
In summary, PRRs play a key role in first-line defense by initiation of innate immunity. This makes them 
a promising target for therapeutic interventions to manipulate the immune system. PRR-targeting 
strategies can either consist of blocking approaches to reduce excessive signaling present for example 
in autoimmune disorders.145 Alternatively, ligation of PRRs can be therapeutically used in the context 
of antitumor treatments, which were pioneered by Coley’s development of sarcoma treatment with 
a mixture of bacterial toxins.146 Due to their capacity to induce activation and maturation of 
phagocytes, PRR agonists are also used as adjuvants for DC vaccination.147 However, as PRR 
stimulation has also been described to exhibit protumor effects by inducing chronic inflammation, the 
amount and duration of activation needs to be carefully titrated.148 
 
1.3.2. Toll-like receptors 
TLRs, like most of PRRs, are evolutionarily conserved from the worm Caenorhabditis elegans to 
mammals.139, 149 They received their name from the similarity to the Toll protein that is essential for 
the development of embryonic dorsoventral polarity and for the antifungal response in Drosophila.150-
152 TLRs are type I transmembrane proteins that are characterized by varying numbers of leucine-rich-
repeat (LRR)-containing ectodomains and an intracellular Toll/IL-1R homology (TIR) signaling 
domain.153 The LRR domains are composed of various numbers of tandem LRR motifs, each of which 
is 24-29 amino acids in length and consists of a β strand and an α helix connected by loops. Ligands 
for TLRs are recognized either by TLR homodimers, heterodimers or by individual TLRs in combination 
with coreceptors.154 TLR signaling is triggered by the ectodomain-mediated dimerization of TLRs and 
involves two distinct pathways (Figure 9): the myeloid differentiation factor 88 (MyD88)-dependent 
and TIR domain-containing adapter-inducing IFN-β (TRIF)-dependent pathway. Both signaling 
pathways lead to the activation of NF-κB and the MAPK pathway to induce inflammatory cytokines.155 
While MyD88 is utilized by all TLRs with the exception of TLR3, TLR3 and TLR4 utilize the TRIF-
dependent pathway.156, 157 
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Figure 9. Simplified scheme of TLR engagement and signaling.   
 
 
To date, thirteen TLR family members are described in mammals, TLR1-TLR10 are found in humans 
and TLR1-9 and TLR11-13 in mice.154 These TLRs are expressed on various immune cells including 
macrophages, DCs, B cells, specific types of T cells and nonimmune cells such as fibroblasts and 
epithelial cells. Expression of TLRs is not static but rather modulated rapidly in response to pathogens 
and cytokines. They can be found both extra- and intracellularly and their cellular 
compartmentalization is modulated by transmembrane and membrane-proximal regions.  
While certain TLRs (TLR1, 2, 4, 5 and 6) are expressed predominantly on the cell surface, others (TLRs 
3, 7, 8 and 9) are present almost exclusively in intracellular compartments such as endosomes. This 
requires internalization of their ligands for signaling processes.137 
All TLRs are activated by different ligands or PAMPs. Human TLRs are divided into three groups: those 
that recognize lipids or lipopeptides (TLR1, 2, 4 and 6), proteins (TLR5) and nucleic acids (TLR3, 7, 8 
and 9).158 TLR1 forms heterodimers with TLR2 (TLR1/2) and recognizes triacyl lipopeptides.159 In 
concert with TLR1 and TLR6 it binds a wide variety of PAMPs including peptidoglycan and lipoproteins 
of Gram-positive bacteria, but also mycoplasma lipopeptides and fungal zymosan.160 TLR4 is crucial for 
the detection of LPS, which is present in the cell wall of Gram-negative bacteria.161 It can also be 
activated by structurally unrelated non-bacterial ligands, such as the plant diterpene paclitaxel or viral 
motifs from the respiratory syncytial virus.137, 162 The highly related nucleic acid binding TLRs found in 
cytoplasmic compartments interact with DNA and RNA derived from viruses or bacteria. TLR3 
recognizes double-stranded RNA (dsRNA), while TLR7 and 8 are responsive to the single-stranded RNA 
(ssRNA) found during viral replication.163, 164 Unmethylated deoxycytidyl-phosphate-deoxyguanosine 
(CpG) motifs that are commonly present in bacterial and viral genomes are recognized by TLR9.165 
Flagellin, which is a principal component of the flagella of both Gram-positive and -negative bacteria, 
interacts with TLR5.166 
TLR10 has also been found to homodimerize or heterodimerize with TLR1 and 2, however its ligand 
and functions are poorly understood.167 Just recently, human immunodeficiency virus (HIV) gp41 
protein was identified as a TLR10 ligand.168 
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1.3.3. Agonists of pattern recognition receptors as adjuvants 
Adjuvants can augment the immune responses to vaccines through a variety of mechanisms, including 
deposition, increased uptake and stability of the antigen and the activation of the immune system. 
The latter is performed by agonists of PRRs.169 Even if nearly all PRRs are potential targets for 
adjuvants, the main focus is put on TLR agonists given the recent success in ongoing phase I and II 
clinical trials. In those, TLR agonists are being used as an adjuvant for peptide vaccinations or in 
combination with radiotherapy.170 
To date, three TLR ligands are FDA-approved. Bacillus Calmette-Guérin (BCG), an attenuated strain of 
Mycobacterium bovis, was initially described to act via TLR2/4 ligation, but was recently shown to also 
interact with TLR9.171 It is mainly used as a vaccine against tuberculosis, but also for the 
immunotherapy of in situ bladder carcinoma.172 Imiquimod, a small molecule TLR7 agonist, has been 
successfully used to treat human papilloma virus (HPV)-induced genital warts and certain skin 
cancers.173 Its use as vaccine adjuvant, for example in melanoma treatment, is still under 
investigation.174, 175 However, a recent clinical trial has demonstrated that pre-treatment with topical 
imiquimod significantly enhanced the immunogenicity of the intradermal trivalent influenza 
vaccine.176 The TLR4 agonist monophosphoryl lipid A (MPL) is a chemically detoxified form of LPS 
derived from Salmonella Minnesota.177 This is still under investigation as an adjuvant in clinical trials 
testing cancer vaccines, but it has been already approved as an adjuvant for a preventive vaccine 
against human papilloma virus (Cervarix™) and Hepatitis B for pre- and haemodialysis patients 
(Fendrix™).178, 179 
Several other TLR agonists, that are not approved yet, are currently tested in pre-clinical and clinical 
settings. Numerous clinical trials explored the potential of using CpG oligodeoxynucleotides (ODNs) as 
immunoadjuvants for cancer vaccines. Even if vaccination using CpG7909 administered together with 
synthetic peptide antigens was able to expand antigen-specific CD8+ T cells in several cancer entities, 
clinical outcomes were not convincing enough.180, 181 The synthetic and stabilized analog of dsRNA 
poly(I:C) interacts with TLR3 and has been developed to mimic the response to RNA virus infection. 
Under the commercial name Hiltonol it has been used in combination with DC-based vaccines in 
glioblastoma and pancreatic cancer, which showed a good safety profile and disease stabilization in 
some patients.182, 183 The TLR5 adjuvant entolimod is a pharmacologically optimized flagellin derivative 
of Salmonella dublin that retains the two constant regions (D0/D1) essential for TLR5 binding. In the 
first instance, studies have established entolimod as a potential treatment for lethal radiation 
exposure, for which it had an excellent safety profile even after systemic delivery.184, 185 It 
demonstrated promising activity as an adjuvant and induced potent anti-viral immune responses in 
animal and clinical trials, when it was either fused to antigens or administered separately with 
vaccines.186-188 As it has been shown to elicit direct antitumoral effects as well, a combination with DC 
vaccines in the cancer setting would be a logical consequence.189-191 Due to the most recent pandemic 
outbreak of COVID-19, great hopes are placed on the mRNA-based vaccines, which are among others 
developed by the German biotech companies CureVac and BioNTech. The mRNA not only encodes for 
the antigen that is expressed by the host translation machinery and subsequently processed and 
presented. Importantly, it also elicits self-adjuvant effects, as the ssRNA is recognized by TLR7/8. 
Initially being developed as individualized cancer vaccines mostly encoding for neoantigens, their 
evaluation in first clinical trials showed encouraging results.192 As this still represents a new approach, 
the efficacy of mRNA-based vaccines both in the treatment of diseases but also in the prevention of 
(viral) diseases has yet to be proven.  
Other PRR agonists can also be used as adjuvants. The cytosolic PRR STING has attracted attention as 
another promising target for anticancer drug development. In a mouse model, the STING activator c-
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di-AMP exerted superior adjuvant properties compared to poly(I:C)/CpG formulation when it was 
combined with a soluble protein vaccine or Dec205-mediated antigen targeting to DCs.193 DC 
vaccination adjuvanted with the STING agonist 2´3´-cGAMP elicited protective antitumor and antiviral 
CD8+ T cell responses both in vitro and in vivo.194 Still, clinical translations were not successful so far 
and need further investigation.195 
 
1.4. Acute myeloid leukemia 
1.4.1. AML pathogenesis and therapy options 
Acute myeloid leukemia (AML) is the most common form of acute leukemia with an incidence that 
increases with age. The disorder arises in a malignantly transformed multipotential hematopoietic 
stem cell that acquires successive genomic alterations leading to abnormal differentiation and 
proliferation properties.196 The leukemic blasts expand clonally and accumulate in the bone marrow, 
blood and extramedullary tissues. There, they repress cells of normal hematopoiesis resulting in 
anemia, granulocytopenia and thrombocytopenia.197, 198 AML is a remarkably complex malignancy 
with a high amount of genetic, epigenetic and phenotypic heterogeneity. Typically, multiple malignant 
clones coexist in patients. As each subclone exhibits a unique pattern of genetic and epigenetic 
abnormalities, they also differ in the treatment response. The molecular and cytogenetic 
abnormalities of AML cells involve mutations in critical genes of normal cell development and cellular 
survival. Thus, targeting this pathways without inducing side effects remains a challenge.196 This may 
explain why AML therapy has not significantly improved over the last 30 years and why advancing the 
treatment has been an extraordinary challenge.197 
Patients are categorized according to cytomorphologic and cytochemical characteristics to improve 
risk-stratification and identification of the best therapeutic options.199 Conventional treatment 
consists of intensive induction chemotherapy using cytarabine and anthracycline that induces 
complete cytomorphological remission in up to 80% of patients. Subsequently, patients undergo a 
consolidation or post-remission therapy that is critical for elimination of minimal residual disease 
(MRD). It consist of several cycles of intermediate-dose cytarabine chemotherapy or, depending on 
the genetic risk profile, allogeneic hematopoietic stem cell transplantation (HSCT).197, 200 Standard 
therapy cures 35 to 40% in adult patients with age younger than 60.197 However, most patients 
experience recurrence of the disease, especially in older patients that are not eligible for intensive 
chemotherapy and HSCT. In this patients, remaining leukemic cells reconstituting the MRD can be 
found in the bone marrow, that are of high prognostic value to assess the risk of relapse and long-
term survival.201 These cells presumably originate from chemoresistant leukemic stem cells (LSCs) with 
the ability to reinitiate and sustain the disease.202, 203  
Novel targeted therapies and immunotherapies may provide suitable alternate therapeutic 
approaches especially in patients not eligible for HSCT and to eliminate MRD to prevent relapse.204 
Among targeted therapy substances, seven are already approved by regulatory authorities: the 
antibody-drug conjugate gemtuzumab ozogamicin (GO) and several small molecule immune 
modulators. All act as kinase or cell pathway inhibitors, including the FLT3 inhibitor midostaurin, the 
isocitrate dehydrogenase (IDH) 2 inhibitors enasidenib and the B cell lymohoma 2 (BCL-2) inhibitor 
venetoclax.205, 206 Immunotherapeutic approaches, that primarily target the patients’ immune system 
to indirectly kill the cancer cells, are under continuous development, but not approved so far. 
Monoclonal antibodies, checkpoint inhibitors, NK cell add-back, T cell-based therapies using chimeric 
antigen receptor (CAR) T cells and AML-specific T cell engaging bispecific antibodies (BiTEs) as well as 
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vaccines are promising tools aiming to induce long-lasting leukemia remission.207-210 Among those, 
AMG-330 or flotetuzumab are examples for clinical-stage molecules that engage CD3+ T cells and 
tumor cells by targeting surface antigens CD33 and CD123, respectively.211, 212 Due to the 
heterogeneity of AML, researchers have to move beyond the “one-size-fits-all” approach and 
individualize therapeutic strategies depending on the patients’ disease phenotype and risk factors.213 
Given the variety of options, a combinatorial therapy of different immunotherapies with a focus on 
checkpoint inhibitors might be a highly potent strategy for the treatment of AML in the future.214 
 
1.4.2. Leukemia-associated antigens, neoantigens and therapeutic use 
All immunotherapeutic approaches for AML rely on the recognition of tumor antigens by active 
immune effector cells in the absence of overwhelming counter-regulatory mechanisms.215 Suitable 
antigens are ideally selectively expressed or overexpressed by the malignant cell. Membrane-
expressed and cell lineage antigens for AML, such as the already mentioned CD33 or CD123 suitable 
for all antibody-based therapies, are rarely cancer-specific. Targeting intracellular leukemia-associated 
antigens (LAAs) provides higher specificity as most of them are typically overexpressed on leukemic 
cells. In addition, it enlarges the total number of possible antigens. Recently, several LAAs have been 
identified including Wilm’s tumor protein 1 (WT1), preferentially expressed antigen in melanoma 
(PRAME) and Fms-like tyrosine kinase 3 internal tandem duplication (FLT3ITD).216  
Highest specificity is provided by targeting neoantigens that arise from tumor-specific mutations or 
gene fusions identified via whole genome and exome sequencing. They can be either restricted to 
individual patients or common for a population of patients. Individual neoantigens in the context of 
AML are produced for example by fusions involving the mixed lineage leukemia (MLL) and histone-
lysine N-methyltransferase 2A (KMT2A) gene. They can occur at multiple breakpoints and with 
multiple partner genes.217, 218 Mutations in WT1 produce semi-personal rather than shared 
neoantigens.219, 220 At the other end of the spectrum are highly recurrent mutations, exemplified by 
missense mutations in IDH 1 or 2 and exon 12 mutations in nucleophosmin 1 (NPM1).221-223 The latter 
one is arguably the most prominent target in this regard, as it is an essential AML driver gene and 
mutations thereof occur in the same hotspot in 30-35% of all AMLs.224 The 4 basepair frameshift 
mutation leads to a C-terminal alternative reading frame of 11 amino acids that can be specifically 
recognized by CTLs. It has been also proposed that the immunogenicity of mutated NPM1 (mNPM1)-
derived neoepitopes might add to the favorable prognosis of AML patients with NPM1 mutations.225 
There are also limitations of targeting neoantigens in hematologic malignancies, such as the low 
number of protein-coding mutations and the HLA-restriction.226 However, neoantigen-directed 
immunotherapy is exceptionally promising, not only because of the high tumor specificity of 
neoantigens, but also because the aberrant protein often plays an indispensable role in the malignant 
phenotype.227 This led to the assumption that targeting a single high-quality neoantigen can be 
sufficient for disease control or even cure.228-230 
Therapeutic targeting of LAAs or neoantigens can either involve vaccination strategies using peptides 
and DCs or T cell-based therapies such as adoptive T cell transfer. LAAs are therapeutically used most 
commonly for peptide or ex vivo DC vaccines. For several LAAs vaccination trials have already been 
initiated. So far, clinical Phase I/II trials investigating LAA-specific peptide vaccines have demonstrated 
immunological and molecular responses that translate into clinical efficacy in up to half of the 
vaccinated AML patients.231 DC vaccines were also tested in the post-HSCT and advanced disease 
setting as well as after chemotherapy-induced remission to prevent relapse.232 Especially in the post-
remission setting of AML, treatment with moDCs loaded for example with WT1 or PRAME or fused to 
AML cells can produce durable remissions and prevent or delay relapse in some high-risk patients.232-
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235 An in vivo DC vaccination strategy with New York esophageal squamous cell carcinoma-1 (NY-ESO-
1) as peptide domain has induced a clinical response in patients with myelodisplastic syndrome (MDS) 
or low blast count AML.236, 237 Besides targeting LAAs by DC vaccination strategies, also T cell-based 
therapies are developed. Chapuis et al. recently showed that WT1-directed TCR gene therapy prevents 
AML relapse after allogeneic HSCT.238 Further, a new therapy has been investigated in vitro and in pre-
clinical models utilizing a T cell bispecific antibody construct that recognizes WT1 in the context of 
HLA-A*02:01.239 As not all patients experienced overt clinical benefit, there is a big need to optimize 
this type of immunotherapy, especially by targeting neoantigens. To our knowledge, no AML-specific 
neoantigen vaccine is investigated so far, neither in vitro nor in vivo. The only immunotherapeutic 
approach in AML targeting a neoantigen was recently developed by Van der Lee et al. They generated 
mNPM1-specific TCR-transduced T cells that showed antitumor efficacy in an AML xenograft mouse 
model.224 As targeting neoantigens by either adoptive T cell therapy or vaccines has demonstrated 
early promise in the clinic in advanced solid tumors, the development of neoantigen-directed (DC) 
vaccines and T cell therapies in AML is further encouraged.72-76, 240, 241  
Collectively, AML antigens exhibit a broad therapeutic application. Different approaches targeting 
LAAs showed clinical responses with room for optimizations, for example by combining it with other 
immunotherapies such as checkpoint inhibitors or antibodies directed against surface receptors with 
killing activity to release neoantigens.232 However, as neoantigen-directed vaccines or T cell-based 
therapies are expected to be more promising per se, a lot of research effort is focused on those and 
first clinical results are eagerly anticipated. 
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2. Objectives 
Dendritic cells (DCs) play a key role at the interface between the native and adaptive immune systems, 
and therefore hold potential for use in the immunotherapy of diseases such as cancer. In particular, 
the high capacity of DCs for processing and presenting antigens makes them an attractive target for 
antigen-delivery. Targeting antigens to DC-specific endocytic receptors by antigen–antibody fusions 
along with immunostimulatory adjuvants have been recently recognized as a promising strategy for 
an effective vaccine that elicits a strong and sustained T cell response against cancer cells. A variety of 
DC-targeting antibodies and formats have been tested in combination with different TLR agonists that 
elicit DC stimulatory potential. In general practice, the adjuvant has been co-administered together 
with the DC-targeting antibody or the peptide vaccine. However, soluble adjuvants led to an antigen-
independent activation of bystander immune cells bearing the risk of adverse events. Also, the co-
delivery of an antigen and adjuvant into the same APC in form of a conjugate resulted in superior 
cross-presentation and peptide-specific T cell activation compared to separate molecule 
administration in vivo.133, 134, 242-244 
We developed multifunctional antibody constructs (MACs) to target and activate DCs in vivo and thus 
combine DC-targeting of antigens and stimulation by TLR ligation in one molecule (Figure 10). We 
aimed to identify a potent combination of antibody and adjuvant while reducing adverse events and 
increasing therapeutic efficacy. MACs consist of an antigen domain including a variable T cell epitope 
that is fused to an αCD40 antibody construct with agonistic function. The constructs were tested in a 
scFv or Fc-silenced IgG1 format. To potentiate therapeutic efficacy, different TLR-ligating domains 
were attached acting as a vaccine adjuvant. Thereby, the TLR4 agonist fluorescein isothiocyanate 
(FITC)-LPS and TLR8 agonist FITC-ssRNA40 were ligated to the scFv-format antibody by interacting with 
an αFITC scFv that was located C-terminally of αCD40. The attachment of the D0/D1 domain of the 
TLR5 agonist flagellin was achieved by genetic fusion to the IgG1- and scFv-format molecules. The 
different MACs were initially compared in vitro in a viral setting by conjugating a cytomegalovirus 
(CMV)-specific peptide derived from the pp65 protein to the antibody. In these proof-of-principle 
studies, the most promising candidate was selected based on capability to enhance DC maturation as 
well as activation and proliferation of antigen-specific T cells.  
The concept was replicated in the leukemia setting by fusing an AML-specific mNPM1-derived 
neoantigen to the DC-targeting antibody. This is of high therapeutic interest, as novel treatment 
options in AML are urgently needed especially in high risk patients. In these experiments, the 
functionality of an mNPM1-coupled αCD40 scFv and IgG1 alone was analyzed and in combination with 
the most potent TLR agonist fusion identified before. 
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Figure 10. Mode of action of multifunctional antibody constructs. 
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3. Materials and Methods 
3.1. Materials 
Unless otherwise stated, all chemicals were purchased from Carl Roth, Merck or Sigma–Aldrich. 
Restriction enzymes for microbiological applications were obtained from Thermo Fisher Scientific and 
primers from Metabion. Cell culture media were obtained from Thermo Fisher Scientific and cell 
culture supplies from Sarstedt and VWR unless indicated otherwise. 
 
3.1.1. E.coli strains  
The E.coli strain XL1 Blue used for cloning was purchased from Stratagen and made chemically 
competent as previously described.245 This strain was cultured in lysogeny broth (LB) media (10 g/l 
tryptone, 5 g/l yeast extract, 5 g/l NaCl, 1.3 ml/l NaOH) and plated in LB agar (LB-Lennox media with 
15 g/l agar). 
 
3.1.2. Healthy donor’s material 
Peripheral blood samples were collected from healthy donors after written informed consent in 
accordance with the Declaration of Helsinki and approval by the Institutional Review Board of Ludwig-
Maximilians-University. Peripheral blood from healthy donors was the source of PBMCs, monocytes 
and T cells. 
 
3.1.3. FITC-coupled and uncoupled TLR agonists 
The following commercial TLR agonists, optionally FITC-labeled, were used during this study (Table 1). 
Dried ssRNA40 from Metabion was re-constituted in nuclease-free IDTE pH 7.5 buffer (Integrated DNA 
Technologies) to a stock concentration of 100 µM. For microscopy studies 6´FAM-ssRNA40-Atto488-
3´, a FITC-coupled ssRNA40 with an additional 3´Atto488 label, was used based on an expected 
quenching of the FITC fluorescence and to ensure sufficient fluorescence stability during microscopy. 
Table 1. Commercial TLR agonists. 
TLR agonist Company 
6´FAM-ssRNA40 (hereafter named FITC-
ssRNA40) 
Metabion 
6´FAM-ssRNA40-Atto488-3´ (hereafter named 
FITC-ssRNA40-Atto488) 
Metabion 
FITC-LPS Sigma–Aldrich 
LPS Sigma–Aldrich 
ssRNA40 Metabion 
 
3.1.4. Plasmids 
Table 2. Vector backbones used for protein expression. 
Vector Company 
pFUSE-CHIg-hG1 InvivoGen 
pFUSE-CLIg-hk InvivoGen 
pSecTag2/Hygro C Life Technologies 
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Table 3. Expression vectors. 
Name Encoded sequence Tag 
pFUSE-CHIg - αCD40 VH Heavy chain of hCD40-specific IgG1 Fc 
pFUSE-CHIg - αCD40 VHFlg Heavy chain of hCD40-specific IgG1/flagellin D0/D1 
domain 
Fc 
pFUSE-CHIg - αCD40 VHmFlg  Heavy chain of hCD40-specific IgG1/flagellin D0/D1 
domain R90A E114A 
Fc 
pFUSE-CHIg - αHer2 VH Heavy chain of hHer2-specific IgG1 Fc 
pFUSE-CHIg - αHer2 VHFlg Heavy chain of hHer2-specific IgG1/flagellin D0/D1 
domain 
Fc 
pFUSE-CHIg - αHer2 VHmFlg Heavy chain of hHer2-specific IgG1/flagellin D0/D1 
domain R90A E114A 
Fc 
pFUSE-CLIg - αCD40 VLCMV Light chain of hCD40-specific IgG1/amino acid 
sequence 487–508 of CMV pp65 protein 
Fc 
pFUSE-CLIg - αCD40 VLmNPM1 Light chain of hCD40-specific IgG1/amino acid 
sequence 277–298 of mutated NPM1 protein 
Fc 
pFUSE-CLIg - αHer2 VLCMV Light chain of hHer2-specific IgG1/amino acid 
sequence 487–508 of CMV pp65 protein 
Fc 
pFUSE-CLIg - αHer2 VLmNPM1 Light chain of hCD40-specific IgG1/amino acid 
sequence 277–298 of mutated NPM1 protein 
Fc 
pSecTag2 - 
αCD40.Flg.αFITCCMV 
hCD40-specific scFv/flagellin D0/D1 domain/FITC-
specific scFv/amino acid sequence 487–508 of CMV 
pp65 protein 
N-His6 
pSecTag2 - 
αCD40.mFlg.αFITCCMV 
hCD40-specific scFv/flagellin D0/D1 domain R90A 
E114A/FITC-specific scFv/amino acid sequence 487–
508 of CMV pp65 protein 
N-His6 
pSecTag2 - 
αCD40.αFITC.TATCMV 
hCD40-specific scFv/FITC-specific scFv/HIV TAT 
CPP/amino acid sequence 487–508 of CMV pp65 
protein 
N-His6 
pSecTag2 - αCD40.αFITCCMV hCD40-specific scFv/FITC-specific scFv/amino acid 
sequence 487–508 of CMV pp65 protein 
N-His6 
pSecTag2 - 
αCD40.αFITCmNPM1 
hCD40-specific scFv/FITC-specific scFv/amino acid 
sequence 277–298 of mutated NPM1 protein 
N-His6 
pSecTag2 - 
αHer2.Flg.αFITCCMV 
hHer2-specific scFv/flagellin D0/D1 domain/FITC-
specific scFv/amino acid sequence 487–508 of CMV 
pp65 protein 
N-His6 
pSecTag2 - 
αHer2.mFlg.αFITCCMV 
hHer2-specific scFv/flagellin D0/D1 domain R90A 
E114A/FITC-specific scFv/amino acid sequence 487–
508 of CMV pp65 protein 
N-His6 
pSecTag2 - 
αHer2.αFITC mNPM1 
hHer2-specific scFv/FITC-specific scFv/amino acid 
sequence 277–298 of mutated NPM1 protein 
N-His6 
pSecTag2 - 
αHer2.αFITC.TATCMV 
hHer2-specific scFv/FITC-specific scFv/HIV TAT 
CPP/amino acid sequence 487–508 of CMV pp65 
protein 
N-His6 
pSecTag2 - αHer2.αFITCCMV hHer2-specific scFv/FITC-specific scFv/amino acid 
sequence 487–508 of CMV pp65 protein 
N-His6 
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3.1.5. Amino acid sequences 
Table 4. Amino acid sequences of binding modules and ligands. 
Name sequence 
αCD40 scFv disufide 
stabilized 
(VH – (G4S)3 – VL) 
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQCLEWMGWIN
PDSGGTNYAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARDQPLGYCTN
GVCSYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSVSASVGDRV
TITCRASQGIYSWLAWYQQKPGKAPNLLIYTASTLQSGVPSRFSGSGSGTDFTLTISS
LQPEDFATYYCQQANIFPLTFGCGTKVEIK 
αCD40 VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
PDSGGTNYAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARDQPLGYCTN
GVCSYFDYWGQGTLVTVSS 
αCD40 VL DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKAPNLLIYTASTLQS
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANIFPLTFGGGTKVEIK 
αHer2 scFv 
(VL – (G4S)4 – VH) (4D5-8-
derived, kindly provided 
by Prof. Matthias Peipp) 
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYS
GVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRGGGGS
GGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQ
APGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYY
CSRWGGDGFYAMDYWGQGTLVTVS 
αHer2 VH EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTN
GYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDY
WGQGTLVTVS 
αHer2 VL DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYS
GVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKR 
αFITC scFv  
(VH – (G4S)3 – VL) 
(kindly provided by Prof. 
Andreas Plückthun) 
QVQLVESGGNLVQPGGSLRLSCAASGFTFGSFAMSWVRQAPGGGLEWVAGLSA
RSSLTHYADSVKGRFTISRDNAKNSVYLQMNSLRVEDTAVYYCARRSYDSSGYWGH
FYSYMDVWGQGTLVTVSSGGGGSGGGGSGGGGSQSVLTQPSSVSAAPGQKVTIS
CSGSTSNIGNNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSKSGNSASLDIS
GLQSEDEADYYCAAWDDSLSEFLFGTGTKLTVL 
Flagellin D0/D1 domain 
separated by a GSGGG 
linker (± R90A and E114A) 
(kindly provided by Prof. 
Bärbel Stecher) 
AQVINTNSLSLLTQNNLNKSQSALGTAIERLSSGLRINSAKDDAAGQAIANRFTANIK
GLTQASRNANDGISIAQTTEGALNEINNNLQRVRELAVQSANSTNSQSDLDSIQAEI
TQRLNEIDRVSGQTQFNGVKVLAQDNTLTIQVGANDGETIDIDLKQINSQTLGLDT
GSGGGAEAAATTTENPLQKIDAALAQVDTLRSDLGAVQNRFNSAITNLGNTVNNL
TSARSRIEDSDYATEVSNMSRAQILQQAGTSVLAQANQVPQNVLSLLR 
Extracellular domain of 
CD40 
EPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCGESEFLDTWNRETHC
HQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCVLHRSCSPGFGVK
QIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETKDLVVQQAGTNKTDVVCGP
QDRLR 
Human IgG1 Fc GADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF
NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ
PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ 
HIV-derived TAT CPP 
sequence246 
YGRKKRRQRRRA 
sequence 487–508 of 
CMV pp65 protein (CMVNLV 
epitope sequence bold) 
QAGILARNLVPMVATVQGQN 
sequence 277–298 of 
mutated NPM1 protein 
(mNPM1CLA epitope sequence 
bold) 
RMTDQEAIQDLCLAVEEVSLRK 
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3.1.6. Commercial antibodies and live/dead stains 
Table 5. Commercial antibodies for flow cytometry. 
Antigen Fluorophore Reactivity Isotype Clone Company 
CD2 APC human Mouse IgG1, κ RPA2.10 BioLegend 
CD3 APC human Mouse IgG2a, κ HIT3a BioLegend 
CD8 FITC human Mouse IgG1, κ SK1 BioLegend 
 PerCP-
eFluor710 
human Mouse IgG1, κ SK1 eBioscience 
CMVNLV-
specific TCR 
(dextramer) 
PE human   Immudex 
IFN-γ PE human Mouse IgG1, κ B27 BioLegend 
TNF-α APC human Mouse IgG1, κ MAb11 BioLegend 
CD80 BV510 human Mouse IgG1, κ 2D10 BioLegend 
CD83 PerCP-Cy5.5 human Mouse IgG1, κ HB15e BioLegend 
CD86 APC human Mouse IgG1, κ BU63 BioLegend 
Dec205 PE human Mouse IgG1, κ HD30 BioLegend 
HLA-DR Pacific Blue human Mouse IgG2a, κ L243 BioLegend 
Penta∙His AF488 or 
AF647 
human Mouse IgG1  Qiagen 
IgG1 Fc FITC human Rat polyclonal 
IgG 
 BioLegend 
 
Table 6. Commercial live/dead stains for flow cytometry. 
Live/dead stain Company 
7-AAD BioLegend 
LIVE/DEAD™ Fixable Aqua Thermo Fisher Scientific 
Zombie Green™ Fixable 
Viability Kit 
BioLegend 
 
3.1.7. Buffers and media 
Table 7. List of standard buffers used for biochemical and cell culture methods. 
Buffer Components 
10×PBS (1 l) 80 g NaCl, 2 g KCl, 14.4 g Na2-HPO4 x 2 H2=, 2 g KH2PO4 (pH 7.4) 
20×SDS running buffer 0.2% SDS, 179 g/l triethanolamine, 143.3 g/l tricine 
4×Laemmli buffer 0.11 M Tris base (pH 6.8), 16% /v/v) glycerol, 4% (w/v) SDS, 5% (v/v) β-
mercaptoethanol, 0.05% (w/v) bromophenol blue 
Biacore regeneration 
buffer 
3 M MgCl2 
Biacore sample and 
running buffer  
HBS-EP pH 7.4 
Coomassie stain 50% (v/v) ethanol, 7% (v/v) acetic acid, 0.2% (w/v) Coomassie Brilliant 
Blue R250 
Elution buffer for Fc-
based purification 
0.1 M Citrate, pH 3 
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Elution buffer for His6-
purification 
1×PBS + 200 mM Imidazole, pH 7.4 
FACS Buffer 1% (v/v) FBS, 1 mM EDTA in 1×PBS 
Neutralization buffer for 
Fc-based purification 
1 M Tris-HCl, pH 9 
Wash buffer for Fc-
based purification 
50 mM Tris-HCl, pH 7.5, ± 500 mM NaCl 
Wash buffer for His6-
purification 
1×PBS + 10 mM Imidazole 
 
Table 8. List of commercial media and buffers for cell culture. 
Media and buffers Company 
DMEM Thermo Fisher Scientific 
DPBS Thermo Fisher Scientific 
Expi293 Expression 
Medium 
Thermo Fisher Scientific 
Nuclease-free water pH 
7.5 
Integrated DNA Technologies (IDT) 
RPMI 1640 + GlutaMAX Gibco, Thermo Fisher Scientific 
VLE RPMI Biochrom 
X-VIVO Lonza 
 
Table 9. List of media and buffers for E.coli. 
Buffer Components 
LB medium (1 l) 10 g bacto tryptone, 5g yeast extract, 5 g NaCl, 1.3 ml NaOH 
LB agar (1 l) LB medium + 15 g agar 
TSS buffer LB medium with 10% (w/v) PEG 6000, 5% (v/v) DMSO, 5 mM MgSO4 (pH 
6.5-6.8), frozen at -20°C 
 
3.1.8. Technical equipment 
Table 10. List of technical equipment. 
Equipment Company 
Aekta Purifier 100 GE Healthcare 
Agarose gel electrophoresis system Bio-Rad 
Biacore X100 GE Healthcare 
Cascade II EMCCD camera Photometrics 
Cell culture laminar-flow BDK Luft- und Reinraumtechnik GmbH 
CM5 Chip GE Healthcare 
Countess automated cell counter Thermo Fisher Scientific 
Cytoflex LX Beckmann Coulter 
Deltavision OMX V3 microscope General Electric 
FACSAriaIII BD Biosciences 
Guava easyCyte 6HT Merck Millipore 
Hemacytometer Neubauer improved Brand GmbH and Co KG 
HeraCell CO2 incubator Thermo Fisher Scientific 
Innova 44 Shaker New Brunswick Scientific 
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Inverted laboratory microscope Leica 
DM IL LED 
Leica 
Irradiation device XStrahl RS225 XStrahl 
Microplate reader Infinite M1000 Pro Tecan 
Mr. Frosty freezing container Thermo Fisher Scientific 
Multitron cell incubator Infors HT 
Nanodrop ND-1000 Peqlab Biotechnologies GmbH 
pH-meter 766 Knick 
Rotana 460 RT centrifuge Hettich 
Sartorius scale LE 22025 Sartorius AG 
Sorvall RC6+ centrifuge Thermo Fisher Scientific 
T personal thermocycler Biometra 
Tabletop centrifuges Eppendorf 
Thermomixer F1.5 Eppendorf 
UPlanSApo objective Olympus 
 
3.1.9. Software 
Table 11. List of software. 
Software Company 
ApE – A plasmid Editor version 2.0.36 M. Wayne Davis 
GraphPad Prism version 6 and 8.2 GraphPad Software Inc. 
InCyte Software version 3.1.1. Merck Millipore 
ImageJ Wayne Rasband (NIH) 
softWoRx 6.0 Beta 19 unreleased 
 
3.2. Molecular biology methods 
3.2.1. Molecular cloning 
All MACs were generated using conventional molecular biology methods. The αCD40 scFv was derived 
from the αCD40 antibody CP-870,893 (selicrelumab, clone 21.4.1, Hoffman-La Roche) with variable 
heavy and variable light chains connected by a (G4S)3 linker.247, 248 It was disulfide stabilized via cysteins 
introduced at VH44 and VL100.249 The sequence of the αFITC scFv was published by Plückthun et al.250 
The specificity control contained an αHer2 scFv derived from the 4D5-8 clone (trastuzumab, Hoffman-
La Roche) that was published elsewere.251, 252 The flagellin D0/D1 domain, separated by a GSGGG 
linker, was cloned by Siret Tahk from genomic DNA of Salmonella typhimurium strain SL1344 that was 
kindly provided by Prof. Dr. Bärbel Stecher. Coding sequences for all scFv molecules were cloned into 
the mammalian expression vector pSecTag2/HygroC (Thermo Fisher Scientific) containing the Ig kappa 
(Igκ) leader sequence and an N-terminal His6-tag. The first scFv was flanked by SfiI restriction sites for 
possible module exchanges between CD40 and Her2. Coding sequences for IgG1 format molecules 
were cloned into mammalian pFUSE expression vectors, pFUSE2-CLIg-hκ for light chain sequences and 
pFUSE-CHIg-hG1 for heavy chain sequences. The Fc-region of the IgG1 backbone was silenced using 
PGLALA mutations.124 The antigen domain contained either a sequence of the CMV-specific pp65 
protein (CMV487–508, abbreviated with CMV) including the immunodominant CMV495–503 epitope 
(NLVPMVATV, abbreviated with CMVNLV), or the mutated NPM1-derived NPM1277–298 protein (mNPM1) 
that comprises the mNPM1288–296 epitope (CLAVEEVSL, abbreviated with mNPM1CLA). In the scFv 
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format, the αFITC was cloned C-terminally of αCD40 and separated by a (G4S)4 linker and the peptide 
domain at the C-terminus was separated by a G4S linker. In the IgG1 format, the antigen domain was 
cloned to the C-termini of the light chains and flagellin to the heavy chains, both separated by (G4S)4 
linkers.  
General molecular cloning techniques such as site-specific cleavage of DNA with restriction enzymes, 
dephosphorylation and ligation as well as size-dependent separation of DNA fragments by agarose gel 
electrophoresis were conducted according to standard protocols.253 Commercially available enzymes 
and ready-made kits were used following manufacturer’s instructions. Plasmid DNA was isolated from 
E. coli XL1 blue using NucleoSpin Plasmid EasyPure kit (Macherey-Nagel). For the purification of DNA 
from agarose gels the NucleoSpin Gel and PCR clean-up kit (Macherey-Nagel) was used. Sequencing 
of all generated DNA vectors was performed at Eurofins Genomics to ensure correct cloning. 
 
3.2.2. PCR and site-directed mutagenesis 
Polymerase chain reaction (PCR) was utilized to amplify the coding sequences of different modules 
from plasmid DNA. If necessary, primer sequences included sequences encoding affinity tags, leader 
sequences or linkers. PCR reactions were performed using Phusion Flash High-Fidelity PCR Master Mix 
(Thermo Fisher Scientific) or KOD Hot Start Master Mix (Merck Millipore), which was used in 
combination with primers exhibiting high melting temperatures. The following table shows common 
PCR reactions with Phusion Flash in comparison to KOD Hot Start Master Mix that both contained 20-
50 ng DNA template and 0.5 µM of each primer. 
Table 12. Conventional PCR programs for Phusion Flash and KOD Hot Start Master mix. 
Step Phusion Flash KOD Hot Start 
 Temperature Time Temperature Time 
Initial 
denaturation 
98°C 30 s 95°C 2 min 
Denaturation 
Annealing 
Extension 
(20-30 cycles) 
98°C 
Ta of primers 
72°C 
30 s 
30 s 
15 s/kb 
95°C 
Ta of primers 
70°C 
 
20 s 
10 s 
10-25 s/kp 
Final extension 72°C 5-10 min 70°C 5-10 min 
Hold  16°C 
Ta: annealing temperature 
Site-directed mutagenesis was used to generate point mutations, in particular PGLALA for Fc-silencing 
and disulfide stabilization of the αCD40 scFv, but also to delete parts of DNA sequences by introducing 
stop codons. The 5´and 3´end of primer pairs surrounding the mutation should allow homology pairing 
of at least 20 bp. For the mutagenesis PCR reaction, 20-50 ng DNA template were incubated with 0.05 
µM of each primer and Phusion Flash Master Mix following the protocol in table 12. To remove 
template DNA, the reaction was subsequently digested with FastDigest DpnI for 30 min at 37°C. 
Afterwards, the DNA was transformed into chemically competent XL1 blue cells and the DNA isolated 
from single clones was sequenced according to 3.2.1. 
 
3.2.3. Transformation of E.coli 
Chemically competent XL1 blue bacterial cells were generated as described previously.245 Briefly, 200 
ml of LB medium containing the appropriate antibiotics were inoculated with 2 ml of an overnight 
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culture and grown until an OD600 of 0.3-0.5 was reached. Then, the cells were centrifuged at 3000 g 
for 5 min at 4°C, resuspended in ice-cold TSS buffer, aliquoted, shock-frozen in liquid nitrogen and 
stored at -80°C until further usage. 
For transformation, 10-100 ng of plasmid DNA was added to 75 µl of competent bacterial cells 
followed by incubation on ice for 15-30 min. Bacteria were heat-shocked for 42 s at 42°C and 
subsequently incubation on ice for 2 min. Subsequently, they recovered in 300 µl LB medium at 37°C 
for 1 h while shaking at 600 rpm. Afterwards, the cells were centrifuged briefly, most of the 
supernatant was removed and the cells were resuspended in the remaining LB medium before plating 
them on LB agar plates supplemented with the appropriate antibiotics. 
Single colonies were picked and inoculated in 5 ml of LB medium containing the appropriate 
antibiotics. The cells were shaken over night at 37°C and plasmid DNA was isolated the next day. 
Table 13. Antibiotics and dilutions used for different vectors. 
Vector Antibiotics  Dilution 
pSecTag2 Ampicillin (100 mg/ml) 1:1000 
pFUSE-CHIg Zeocin (100 mg/ml) 1:4000 
pFUSE-CLIg Blasticidin Ready to use pouches at 100 
µg/ml 
 
3.3. Cell culture methods 
3.3.1. Cell lines and maintenance 
The L-428 cell line derived from a Hodgkin lymphoma was a kind gift from Prof. Marion Subklewe and 
purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ). It was cultured 
in RPMI 1640 + GlutaMAX (Gibco, Thermo Fisher Scientific) supplemented with 10% fetal bovine 
serum (FBS, Gibco, Thermo Fisher Scientific). Expi293F cells were purchased from Thermo Fisher 
Scientific and cultured in Expi293 Expression Medium (Thermo Fisher Scientific).  
All cell lines were grown until the recommended cell density and passaged twice a week. They were 
routinely tested for mycoplasma contaminations. 
 
3.3.2. Recombinant protein expression in Expi293F cells 
All molecules were expressed in Expi293F cells that were co-transfected with the corresponding 
vectors using ExpiFectamine 293 transfection kit (Thermo Fisher Scientific) following the 
manufacturer’s instructions. For the generation of IgG1-format antibodies, heavy and light chains 
were transfected in a 1:1 ratio. Transient expression of all MACs was performed for 5 to 6 days after 
transfection. Due to the Igκ leader sequence in the vectors, the molecules could subsequently be 
purified from the supernatants. For low-expressing plasmids and to generate higher amounts of 
protein, stable cell pools of Expi293F cells expressing scFv contructs were generated. Therefore, 1-2 
days after transfection 300 µl of Expi293F cells were transferred to 3 ml DMEM + GlutaMAX medium 
supplemented with 10% FBS and 50 µg/ml hygromycin B gold (InvivoGen) in a 6-well plate (standard, 
Sarstedt). By changing the medium with antibiotics and removing dead cells, cells that stably 
integrated the plasmid were selected, adhered and grew out in clones. After approximately 3 weeks, 
the stable cell pool could be transferred into shaking culture with Expi293 Expression Medium and 
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cultivated in the presence of 50 µg/ml hygromycin. Subsequently, stable cells were either frozen or 
expanded for protein expression. 
 
3.3.3. Isolation of peripheral blood mononuclear cells from heparinized blood 
PBMCs from healthy donors were separated from heparinized peripheral blood using the Biocoll 
separating solution (Biochrom) and Leucosep tubes (Greiner Bio-One) according to the manufacturer’s 
instructions. In brief, 15 ml of Biocoll solution was preloaded in a 50 ml Leucosep tube by 
centrifugation for 30 s at 1000 g. Heparinized whole-blood samples were diluted with equal volumes 
of Dulbecco’s phosphate buffered saline (DPBS, Thermo Fisher Scientific) and 30ml of the diluted 
blood was added to the Leucosep tube. Tubes were centrifuged for 10 min at 1000 g without breaking. 
Buffy coat containing PBMCs was collected, washed and re-suspended in RPMI 1640 + 10% FBS for 
further use.  
 
3.3.4. Generation of monocyte-derived dendritic cells  
MoDCs were generated within 3 days as described before.106 In brief, monocytes were enriched from 
PBMCs by plastic adherence in flat bottom 6- or 12-well plates with a surface treated for maximum 
adhesion (Nunc, Thermo Fisher Scientific) at a concentration of 0.5-1×107 cells/ml in Very Low 
Endotoxin (VLE) RPMI (Biochrom) supplemented with 1.5% human serum (HS, serum pool of AB 
positive adult males; Institute for Transfusion Medicine, Suhl) – hereafter named DC medium. If 
required, non-adherent cells (NACs) were kept at 37°C until further use three days later. For some 
experiments requiring pure monocytes or DCs (for example for microscopy), monocytes were isolated 
from PBMCs using the Classical Monocyte Isolation kit (Miltenyi Biotec) according to the 
manufacturer’s instructions. Afterwards, monocytes were seeded in Nunc 24-well plates and cultured 
for 48 h at 37°C in DC medium supplemented with 800 IU/ml GM-CSF (Peprotech) and 580 IU/ml IL-4 
(Peprotech) (2d-moDCs). For some experiments, 2d-moDCs were then loaded with MACs ± TLR 
agonists for 24 h followed by different cytokine treatments, depending on which DC maturation state 
should be achieved. If antibody constructs were combined with TLR agonists and if immature moDCs 
(iDCs) were needed, 800 IU/ml GM-CSF, 580 IU/ml IL-4 was added for another 24 h together with 250 
ng/ml PGE2 (Sigma–Aldrich). To generate fully mature moDCs (mDCs), maturation was achieved within 
24 h by the addition of 800 IU/ml GM-CSF, 580 IU/ml IL-4, 250 ng/ml PGE2, 2000 IU/ml IL-1β (R&D 
Systems), 1100 IU/ml TNF-α (Peprotech), 5000 IU/ml IFN-γ (Peprotech), 1 µg/ml R848 (InvivoGen).105, 
106 For some experiments, iDCs and mDCs were loaded with the processed HLA-A*02:01-restricted 
peptides (CMVNLV, mNPM1CLA, JPT Peptide Technologies) for 1.5 h at 37°C in serum-free medium. 
As the VLE RPMI was discontinued at the end of 2019, regular RPMI 1640 + GlutaMAX was used for 
the last experiments while no differences in DC quality were detected. 
 
3.3.5. Generation and expansion of CMVNLV- and mNPM1CLA-specific T cells 
CMV pp65487–495-peptide specific CD8+ T cells (CMVNLV-specific T cells) were generated by Alina Lohner 
from the group of Prof. Marion Subklewe. For this, PBMCs from an HLA-A*02:01+ donor with previous 
CMV infection (CMV+) were isolated. MoDCs were matured as described above, pulsed with 1 µM of 
CMVNLV for 90 min and irradiated with 30 Gy (XStrahl RS225, XStrahl). Autologous CD8+ T cells were 
isolated from NACs using the CD8+ T cell Isolation Kit (Miltenyi Biotec) according to the manufacturer’s 
instructions. T cells and pulsed DCs were co-cultivated at a T cell:DC ratio of 4:1 in RPMI 1640 with 5% 
HS and 30 ng/ml IL-21 (Peprotech) for 72 h. On days 3 and 6, co-cultures were expanded 1:1 by adding 
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medium supplemented with 10 ng/ml IL-15 and IL-7 (Peprotech). On day 9, CMVNLV-specific CMVNLV-
specific dextramer+ and CD8+ T cells were sorted on a FACSAriaIII (BD Biosciences). 
mNPM1288–296-specific CD8+ T cells (mNPM1CLA-specific T cells) were kindly provided by Dr. Marieke 
Griffioen and generated as described previously by the transduction of CD8+ T cells with an mNPM1CLA-
specific TCR.224 
For the expansion of specific T cells, PBMC feeders of two HLA-A*02:01+ and two HLA-A*02:01- donors 
were mixed in equal amounts and pulsed with 1 µM CMVNLV or mNPM1CLA peptide in X-VIVO-15 
medium (Lonza) for 2 h at 37°C. After irradiation with 30 Gy, feeders at a concentration of 2×106 
cells/ml were cultivated with specific T cells at 0.4×106 cells/ml in X-VIVO 15 + 5% HS supplemented 
with 10 ng/ml IL-7 and IL-15 and 0.5 µg/ml PHA-L (Sigma–Aldrich) in a 6-well plate for suspension cells 
(Sarstedt). After 3 days, cultures were fed by replacing half volume of medium with fresh X-VIVO 15 + 
5% HS supplemented with 50 U/ml IL-2 (Peprotech), 20 ng/ml IL-7 and 20 ng/ml IL-15. Using this 
medium T cells were splitted and expanded every 3-6 days. Experiments were performed 9-21 days 
after expansion. Feeding was necessary every 14-21 days. 
 
3.4. Protein biochemistry methods 
3.4.1. Purification of Fc-fusion and IgG1 antibodies from cell culture supernatant 
To purify IgG1-format molecules, cell culture supernatants containing the desired antibodies were 
incubated over night at 4°C with an appropriate amount of nProtein A sepharose 4FF beads (GE 
Healthcare) on a rotating wheel. Beads were collected by centrifugation and loaded into a Bio-Spin 
chromatography column (Thermo Fisher Scientific). Washing steps were performed with 4 column 
volumes of wash buffer for Fc-based purification (see table 7, 50 mM Tris-HCl pH 7.5). Subsequently, 
antibodies were eluted from beads using 6 column volumes of elution buffer (0.1 M citrate pH 3.0) 
followed by neutralization of elution fractions with neutralization buffer (1 M Tris-HCl pH 9.0). All wash 
and elution fractions were collected separately and evaluated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie Brilliant Blue stain (see chapter 3.4.3), 
fractions containing the antibodies of interest were pooled and concentrated using Amicon spin 
concentrators (Merck Millipore). These concentrators were also used to exchange the buffers against 
phosphate buffered saline (PBS) by adding a surplus of PBS during initial centrifugation steps. 
If impurities on the first gel analysis were seen and to remove dimer fractions, a size exclusion 
chromatography (SEC) using a Superdex 200 Increase 10/300 GL column (GE Healthcare) was 
performed as a second polishing step. SEC fractions containing the antibodies were pooled, visualized 
by SDS-PAGE and concentrated. Protein concentration was measured with a spectrophotometer 
(Nanodrop ND-100, Peqlab Biotechnologies GmbH) followed by sample aliquotation, shock freezing in 
liquid nitrogen and storage at -80°C. 
 
3.4.2. Purification of poly-Histidine tagged proteins from cell culture supernatant 
For the purification of His-tagged proteins, cell culture supernatants of transient or stable 
transfections were incubated with Ni-NTA agarose beads (Qiagen) for 2 h at 4°C. After collection, the 
beads were transferred into a Bio-Spin chromatography column and washed with 4 column volumes 
of wash buffer (see table 7, 1×PBS + 10 mM Imidazole) to remove non-specific binding. Subsequently, 
proteins were eluted with 6 column volumes of elution buffer (1×PBS + 200 mM Imidazole). All further 
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steps, including SDS-PAGE, concentration and SEC, were performed as described in the previous 
section. 
 
3.4.3. Denaturing polyacrylamide gel electrophoresis  
The purity of protein samples after purification steps or interaction studies were evaluated by SDS-
PAGE using precast 4-20% Bis-Tris gels of the RunBlue SDS-PAGE Gel System (Expedeon). Protein 
samples were mixed with Laemmli buffer and denatured for 5 min at 95°C. After loading the samples 
onto the gel, it was run at 140 V for 10 min and for another 40-50 min at 180 V in 1×SDS Running 
Buffer. Afterwards, proteins were stained for 30 min using Coomassie Brilliant Blue staining solution 
followed by destaining in water. PageRuler Unstained Protein Ladder (Thermo Fisher Scientific) served 
as size standard. 
 
3.4.4. Thermal unfolding analysis by nanoDSF 
The thermal stability of proteins was determined using nano differential scanning fluorimetry 
(nanoDSF) that measures temperature-dependent changes in the intrinsic fluorescence of 
tryptophane and tyrosine residues (Tycho NT.6, NanoTemper Technologies). For this, 1 µM of protein 
in PBS was absorbed by a capillary that was subsequently placed into the reader. Afterwards, the 
intrinsic protein fluorescence was measured at 330 nM and 350 nM while incubating at increasing 
temperatures. Changes in fluorescence signal indicated transitions in the folding state of the proteins 
and the temperatures at which a transition occurred are named as inflection temperatures (Ti) or also 
melting temperatures (Tm).254 
 
3.5. Binding and interaction studies 
3.5.1. Binding studies by flow cytometry 
Binding analysis of all MACs to CD40 on the DC surface was assessed by incubating CD40-expressing 
cells, such as L-428 cells or iDCs and mDCs, with the respective protein at saturating concentration. 
His-tagged proteins were subsequently detected by secondary staining with a Penta∙His Alexa Fluor 
(AF)488 or AF647 conjugate antibody (Qiagen), IgG1 antibodies by a FITC-coupled αhuman IgG Fc 
(BioLegend). Briefly, 0.5×105 cells were stained with 50 µl of 200 nM MACs, diluted in FACS buffer, if 
not otherwise stated. Cells were incubated for 30 min at 4°C, washed and afterwards stained for 
another 30 min at 4°C in 50 µl of 1:200 diluted Penta∙His or 1:100 diluted αhuman IgG Fc antibody in 
FACS buffer. Subsequently, cells were washed, resuspended in FACS buffer and measured on a Guava 
easyCyte 6HT instrument (Merck Millipore). As analysis, the mean fluorescence intensity (MFI) ratio 
was calculated dividing MFI of the antibody by the MFI of the isotype control. 
 
3.5.2. KD determination by flow cytometry 
To determine equilibrium binding constants (KD, as an affinity and avidity measurement) by flow 
cytometry, L-428 cells were incubated with MACs in a concentration range of 0.005 to 200 nM for 30 
min at 4°C. Cells were washed and subsequently stained with the corresponding secondary antibody 
as indicated before. For evaluation, the maximum MFI was set to 100% and all data points were 
normalized accordingly. The data was fitted with a non-linear regression curve using a one-site specific 
binding model. 
Materials and Methods 
34 
 
3.5.3. KD determination by surface plasmon resonance  
For KD assessment by surface plasmon resonance (SPR) using a Biacore X100 machine (GE Healthcare), 
a CM5 chip (GE Healthcare) was coated with an αhuman Fc capture (GE Healthcare) that reacts with 
the chip’s amino groups at a level of around 8000 response units (RU). The ligand αCD40 IgG1 was 
immobilized on the chip at a level of 100 RU, which was achieved after a contact time of 180 s and 
with an antibody concentration of 1.25 nM. The extracellular domain of CD40 was passed over the 
antibody-coated chip at concentrations ranging from 15.62 to 1000 nM with an association time of 
180 s and a dissociation time of 600 s. The KD was determined by the ratio of the association rate 
constant (kon) and the dissociation rate constant (koff). 
 
3.5.4. Internalization studies by structured illumination microscopy 
To assess internalization of MACs on DCs, moDCs differentiated from magnetically isolated monocytes 
were used. αCD40.αFITCCMV, αCD40CMV and the αHer2 non-specific binding controls were labeled with 
an AF594 Antibody Labeling Kit (Thermo Fisher Scientific) and excess of dye was removed according 
to the manufacturer’s instructions. Similar degrees of labeling were obtained for all antibodies. 200 
nM of MACs and the non-specific binding controls that had been pre-coupled for 30 min with FITC-
ssRNA40 for some experiments were incubated for 90 min at 4°C or at 37°C with iDC and mDCs. For 
samples incubated at 4°C as well and also the αHer2 controls at either temperature, membrane 
staining with an AF488-labeled αHLA-DR antibody was performed for 30 min at 4°C. Next, moDCs were 
transferred onto coverslips using a Shandon Cytospin 3 cytocentrifuge (Thermo Fisher Scientific) for 
10 min at 800 rpm. Cells with the exception of those subjected to membrane staining were prepared 
for intracellular staining by fixation with 4% paraformaldehyde (Sigma–Aldrich) in DPBS followed by 
permeabilization with 0.1% Triton X-100 (Sigma–Aldrich) in DPBS; both treatments were performed 
for 10 min at room temperature. Lysosomes were stained for 30 min at 4°C using αLAMP1 (Novus 
Biologicals) or αEEA1 antibody (Thermo Fisher Scientific), which were detected in a subsequent step 
using a secondary donkey αrabbit AF488 antibody (Thermo Fisher Scientific) for 30 min at 4°C. Post-
fixation took place for 10 min at room temperature with 4% paraformaldehyde followed by nuclear 
staining with 1 µg/ml DAPI (Thermo Fisher Scientific). Finally, the coverslips were mounted onto glass 
slides using Vectashield (Vectorlabs) and sealed with transparent nail polish. 
3D structured illumination microscopy (SIM) acquisition was done in the laboratory of Prof. Heinrich 
Leonhardt on a Deltavision OMX V3 microscope (General Electric) equipped with a 100 × 1.4 oil 
immersion objective UPlanSApo (Olympus), 405 nm, 488 nm and 593 nm diode lasers and Cascade II 
EMCCD cameras (Photometrics). Raw data were first reconstructed and corrected for colour shifts 
with the help of the provided software softWoRx 6.0 Beta 19 (unreleased). In a second step, a custom-
made macro in Fiji finalized the channel alignment and established composite TIFF stacks.255 For better 
presentation of the images all channels were individually adjusted in brightness (exceptions are 
indicated). 
 
3.5.5. Interaction studies by size exclusion chromatography 
SEC techniques were used in order to study the interaction between the αFITC scFv and FITC-labeled 
nucleic acids. 30 µg of αCD40.αFITCCMV and of a FITC-labeled 42 mer dsDNA (ca. 25 kDa) were loaded 
independently on a Superdex 200 Increase 5/150 GL column. Afterwards, 30 µg of the two 
components were mixed, meaning an approximately 2-fold excess of DNA, incubated for 30 min at 
room temperature and run over the column. Elution at a lower volume compared to the single 
components indicated a complex formation.  
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3.5.6. Interaction studies by fluorescence quenching 
To study interaction of FITC-ssRNA40 with of αCD40.αFITCCMV by fluorescence quenching, 10 nM of 
FITC-ssRNA40, diluted in nuclease free water pH 7.5, were incubated with different antibody 
concentrations, ranging from 0.5 to 160 nM in DPBS, for 30 min at room temperature. The samples 
were placed in a black non-binding 96-well plate (Greiner Bio One) and subsequently fluorescence 
intensity with the excitation wavelength of 480 nM and emission wavelength of 520 nM and 
anisotropy as the inversely related readout was measured via the Infinite M1000 Pro reader (Tecan) 
at optimal gain. Quenching of FITC fluorescence in combination with escalating anisotropy at 
increasing antibody concentrations provided evidence for occurring interaction between FITC-
ssRNA40 and the αFITC scFv. The same experiment was also performed using FITC-LPS. 
 
3.5.7. Signaling studies using hTLR5-HEK293 cells 
Signaling studies were performed in the laboratory of Prof. Christine Josenhans using a human TLR5-
expression HEK293-T cell line (hTLR5-HEK293). As a readout, IL-8 secretion was determined using a 
commercially available enzyme-linked immunosorbent assay (ELISA).256 
 
3.6. Functional assays 
3.6.1. Maturation and peptide-loading of immature moDCs 
As described in 3.3.4. the 2d-moDCs were incubated for 24 h with 200 nM antibody constructs 
including CMV- or the mNPM1-specific domains to load the cells with the respective peptide. In some 
experiments, TLR agonists were added either by genetic fusion or by coupling them via an αFITC scFv. 
If mDCs should be generated, a maturation cocktail including IL-4, GM-CSF, PGE2, IL-1β, IFN-γ, TNF-α 
and R848 was added for 24 h. However, if DCs should be left in the immature stage or if the DC 
maturing effect of different stimulations should be investigated, only a reduced cytokine cocktail (IL-
4, GM-CSF and PGE2) was appended. For some experiments, iDCs and mDCs were loaded with the 
already processed peptides (CMVNLV, mNPM1CLA) for 1.5 h.  
In some assays, in which the flagellin-induced DC maturation should be assessed, iDCs were pre-
incubated with a 4-fold excess (200 nM) of an IgA2 αTLR5-blocking antibody or the respective isotype 
control (InvivoGen) for 30 min at 37°C before the addition of 50 nM flagellin fusion molecules to 
determine whether this effect was TLR5-driven. 
To investigate the maturation stage of DCs, that was either induced by the αCD40 binder, the TLR 
ligating domains or the R848-containing cytokine cocktail, expression of maturation markers and 
cytokine secretion was quantified by flow cytometry and compared to iDCs. For this, 
immunofluorescent staining of the cell surface antigens CD80, CD83, CD86 and HLA-DR was performed 
using a panel of fluorescently-conjugated monoclonal antibodies as listed in table 5. Corresponding 
isotype controls were used to determine the MFI ratio. In parallel, IL-6 secretion into the supernatant 
was quantified via cytometric bead array (BD Biosciences) according to the manufacturer’s 
instructions. Surface stained DCs were acquired on a Cytoflex LX flow cytometer (Beckmann Coulter), 
cytokine-bound beads on the Guava easyCyte 6HT. 
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3.6.2. Allogeneic DC–T cell co-cultures  
Immature and mature DCs of an HLA-A*02:01 positive donor were loaded with 200 nM of indicated 
MACs ± TLR agonists or peptides as described in the previous section. Before setting up a co-culture, 
MACs, maturation reagents and peptides were removed by harvesting and washing of the DCs. The 
DCs were cultivated with allogeneic CMVNLV- and mNPM1CLA-specific T cells, that were generated and 
expanded according to section 3.3.5., in a 1:5 ratio for 4-6 h in DC medium containing monesin at 25 
µM and brefeldin A at 10 µg/ml (both Sigma–Aldrich) at 37°C. As a readout for T cell activation, the 
percentage of IFN-γ and TNF-α double positive cells within CD8+ cells was determined by intracellular 
cytokine staining (ICCS). To this end, cells were stained for CD8, fixed and permeabilized using the BD 
Cytofix/Cytoperm Kit according to the manufacturer’s instructions (BD Biosciences) followed by 
intracellular IFN-γ and TNF-α staining and flow cytometric readout on the Guava easyCyte 6HT. 
 
3.6.3. Autologous DC–T cell co-cultures 
DCs were prepared as described in the previous section. Antibody- or peptide-loaded iDCs or mDCs 
were incubated with autologous NACs of a CMV+ and HLA-A*02:01+ donor in a 1:10 ratio in DC medium 
for 6 days. To analyze T cell proliferation, the percentage of CMVNLV-specific T cells within CD8+ T cells 
was determined by staining with a CMVNLV-specific dextramer (Immudex). Cells were acquired on the 
Guava easyCyte 6HT. 
 
3.7. Data plotting and statistical analysis 
Data was analyzed and plotted with GraphPad Prism (GraphPad Software Inc.). Differences in DC 
maturation, T cell activation and proliferation were assessed by the Wilcoxon signed-rank test 
comparing dependent samples of unknown distribution with each other. Statistical significance was 
considered for p-value < 0.05 (*), <0.01 (**), <0.001 (***) and <0.0001 (****), ns = not significant. 
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4. Results  
4.1. Generation and stability of MACs 
4.1.1. Molecule design and cloning 
The systemic co-delivery of TLR agonists together with a DC-based vaccine is a promising strategy to 
enhance vaccine efficacy and to break tolerance to antigens.257 However, systemic administration of 
different immune-stimulatory agents increase the risk of broadly distributed adverse events and, in 
case of small molecules, are often limited by a fast renal clearance. We developed multifunctional 
antibody constructs (MACs) that deliver antigens together with a TLR agonist to DCs. All molecules 
target CD40 on the surface of DCs and consist either of an αCD40 Fc-silenced IgG1 antibody or a single-
chain variable fragment (scFv) thereof. The utilized binding sequences originate from the agonistic 
therapeutic antibody CP-870,893 (clone 21.4.1.) that has been disulfide stabilized in the scFv 
format.247, 248 For proof-of-principle experiments, the antigen domain contained a sequence of the 
CMV-specific pp65 protein (CMV487–508, CMV) which includes the CMV495–503 epitope (NLVPMVATV, 
CMVNLV). In the second part of the thesis, IgG1 format molecules were investigated using the 
mNPM1277–298 peptide (mNPM1) as an antigen domain that comprises the mNPM1288–296 epitope 
(CLAVEEVSL, mNPM1CLA). To couple TLR agonists two different strategies were applied. In one 
approach, FITC-labeled TLR 4 and 8 agonists (FITC-LPS and FITC-ssRNA40) were non-covalently linked 
to the antibody via an αFITC scFv that is flanked by the αCD40 scFv on the N-terminus and the antigen 
domain on the C-terminus (αCD40.αFITCCMV). Alternatively, a truncated version of the TLR5 agonist 
flagellin (Flg) was genetically fused to the antibody (αCD40.Flg.αFITCCMV for scFv format and 
αCD40.FlgCMV for IgG1 format). The flagellin region, including the D0/D1 domain connected by a 
GSGGG linker, was cloned from genomic DNA of Salmonella typhimurium by Siret Tahk and was 
designed analogous to the therapeutic drug entolimod.184, 185 To control specificity of all candidate 
molecules, the CD40-targeting domain was exchanged by an αHer2 binder that was derived from the 
therapeutic antibody trastuzumab. Figure 11 shows the schematic composition of all the tested 
molecules. ScFv-based molecules were cloned into a pSecTag2 vector and for the IgG1 format pFUSE 
vectors for heavy chain and light chain were used. Both contained the Igκ leader sequence to promote 
secretion of the protein into the cell culture media. All domains targeting different entities were 
separated by one or more polyglycine–serine (G4S) units as indicated. 
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Figure 11. Schematic view of MACs. 
The modular composition of the MACs includes an αCD40 scFv or an Fc-silenced IgG1 DC-targeting domain, a CMV-specific 
antigen domain and an immune-stimulatory domain. The latter consisted of either an αFITC scFv to bind FITC-labeled TLR 
agonists or of genetically fused flagellin. As non-specific binding controls, all MACs were also generated with an αHer2 
binding module. The molecules were also cloned with an mNPM1-derived peptide as an antigen domain. 
 
4.1.2. Expression and purification 
The multifunctional antibodies were purified from transiently transfected Expi293F cells in a two-step 
procedure. ScFv molecules were captured from the cell culture supernatant using Ni-NTA agarose 
beads, IgG1 antibodies using protein A sepharose beads. SEC with a Superdex 200 Increase 10/300 GL 
column was performed as a second purification step. αCD40.αFITCCMV, αCD40.Flg.αFITCCMV and 
αCD40CMV did not show any impurities after the bead-based affinity purification (data not shown), but 
for αCD40.FlgCMV two peaks were visible on the chromatogram of the preparative SEC (Figure 12A). 
SDS-PAGE analysis revealed that peak 1 contained a protein of bigger molecular weight, namely 
αCD40.FlgCMV with flagellin fusion, and peak 2 contained only αCD40CMV (Figure 12B). The fractions of 
the first peak were pooled to obtain pure αCD40.FlgCMV protein.  
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Figure 12. Preparative gel filtration profile and SDS-PAGE analysis of αCD40.FlgCMV after protein A-based affinity 
chromatography. 
(A) Chromatogram of preparative SEC with a Superdex 200 Increase 10/300 GL column and (B) SDS-PAGE analysis of 
αCD40.FlgCMV purified via Protein A beads from the supernatant of transiently transfected Expi293F cells. Two peaks of 
different molecular weight were eluting from the column, one peak including heavy chain with flagellin fusion (αCD40.FlgCMV) 
and the other one without flagellin attached (αCD40CMV). 
 
Molecule purity subsequent to the two-step purification was further evaluated by SDS-PAGE analysis 
and analytical gel filtration (Figure 13). As depicted on SDS-PAGE, all molecules without flagellin were 
clean and corresponded to the computed masses. Both molecules with flagellin fusion 
(αCD40.Flg.αFITCCMV and αCD40.FlgCMV) showed a higher apparent molecular weight than the 
theoretical value due to glycosylation of flagellin (for example 90 kDa determined by SDS-PAGE vs 80 
kDa computed mass for heavy chain fusion) (Figure 13A-B). αCD40.Flg.αFITCCMV was visible as a double 
band on SDS-PAGE, which could not be separated by SEC due to just a minimal difference in size. For 
αCD40.FlgCMV in the IgG1 format, SDS-PAGE analysis revealed that still a low amount of heavy chain 
lacking the flagellin domain was present after preparative SEC (Figure 13A). Nevertheless, analytical 
gel filtration as a second quality control of the proteins demonstrated clean chromatograms for all 
molecules including flagellin fusions (Figure 13C-D). αCD40CMV and αCD40.αFITCCMV could be produced 
in reasonable amounts. Notably, the insertion of the flagellin domain reduced the yield in the scFv 
format by approx. 2-fold and in the IgG1 format by 6-fold (Table 14). 
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Figure 13. SDS-PAGE analysis and analytical gel filtration profile of purified and concentrated MACs subsequent to the 
two-step purification procedure. 
(A) SDS-PAGE evaluation of purified proteins (3 µg). (B) PNGase F digestion of αCD40.Flg.αFITCCMV and αCD40.FlgCMV (3 µg) 
for 1 h at 37°C and subsequent SDS-PAGE evaluation resulted in a reduction of molecular weights due to removal of N-linked 
glycosylations. (C, D) Analytical SEC chromatograms of αCD40 scFv (C) and IgG1 (D) antibodies (30 µg) with and without 
flagellin fusion using a Superdex 200 Increase 5/150 GL column.  
 
Table 14. Expression yields. 
Molecule Yield (Mean ± SD of n = 3 purifications) 
αCD40.αFITCCMV 13.3 ± 0.8 mg/ml 
αCD40.Flg.αFITCCMV 6.0 ± 3.0 mg/ml 
αCD40CMV 19.5 ± 8.5 mg/ml 
αCD40.FlgCMV 3.3 ± 1.2 mg/ml 
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4.1.3. Thermal stability and unfolding 
The thermal stability and unfolding of the molecules were investigated using nanoDSF that employs 
intrinsic tryptophan or tyrosin fluorescence. Figure 14 shows the unfolding profile and table 15 the 
melting temperatures of all molecules. αCD40 IgG1 antibodies exhibited higher melting transitions 
compared to scFv format molecules. The insertion of the flagellin domain did not influence thermal 
stability of both scFv- and IgG1-based molecules.  
 
Figure 14. Thermal unfolding of MACs. 
Thermal stability of αCD40.αFITCCMV and αCD40.Flg.αFITCCMV (A) as well as of αCD40CMV and αCD40.FlgCMV (B) as determined 
by nanoDSF.  
 
Table 15. Melting temperatures (Tm) 
Molecule Tm (1) Tm (2) 
αCD40.αFITCCMV 68.8°C 76.0°C 
αCD40.Flg.αFITCCMV 68.5°C 75.6°C 
αCD40CMV 72.5°C 84.1°C 
αCD40.FlgCMV 71.7°C 84.1°C 
 
To determine time- and temperature-dependent stability, proteins were stored for up to 14 days at 
4°C and for up to 7 days 37°C, large aggregates were separated by centrifugation and the supernatant 
was evaluated by SDS-PAGE. None of the molecules showed any substantial degradation compared to 
freshly thawed proteins and all antibodies remained intact at least for 7 days at 37°C and for 14 days 
at 4°C (Figure 15). This confirms that the proteins were sufficiently stable at physiological conditions. 
 
A B
40 60 80 100
-0.005
0.000
0.005
0.010
0.015
0.020
Fi
rs
t 
d
er
iv
at
iv
e 
(r
at
io
)
CD40.FlgCMV
CD40CMV
Temperature (°C)
40 60 80 100
-0.0025
0.0000
0.0025
0.0050
0.0075
0.0100
Fi
rs
t 
d
er
iv
at
iv
e 
(r
at
io
)
CD40.Flg.FITCCMV
CD40.FITCCMV
Temperature (°C)
Results 
42 
 
 
Figure 15. Time- and temperature-dependent stability of MACs. 
SDS-PAGE analysis of 3 µg of αCD40.αFITCCMV and αCD40.Flg.αFITCCMV (A) as well as of αCD40CMV and αCD40.FlgCMV (B) freshly 
thawed and after incubation at 4°C and 37°C for indicated time points in PBS. 
 
4.1.4. Functionality of the αFITC domain 
To prove functionality of the αFITC scFv domain, the interaction of αCD40.αFITCCMV with a FITC-labeled 
DNA and ssRNA was verified via analytical SEC and measurement of fluorescence quenching and 
anisotropy. Figure 16A shows that incubation of αCD40.αFITCCMV with a FITC-labeled 42 mer DNA 
oligonucleotide results in the formation of a complex that elutes at an earlier volume indicating a 
higher molecular weight from the Superdex 200 Increase 5/150 GL column compared to the single 
molecules. As a 2-fold excess of DNA was used, remaining unbound DNA was eluted subsequently to 
the complex. 
For the fluorescence quenching experiment, increasing concentrations of αFITC scFv were incubated 
with 10 nM of FITC-ssRNA40 leading to a decrease in FITC fluorescence (Figure 16B). In parallel, 
anisotropy as the inversely related readout increased indicating an interaction of the FITC-ssRNA with 
the αFITC module. A complete quenching was observed at a 4-fold excess of αFITC scFv, which could 
be due to the presence of some non-functional protein. When the assay was performed by replacing 
FITC-ssRNA40 with FITC-LPS, the same results were obtained (data not shown). 
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Figure 16. Interaction studies of αCD40.αFITCCMV and FITC-coupled nucleic acids. 
(A) 30 µg of αCD40.αFITCCMV, a FITC-labeled 42 mer DNA or the complex of both were run over a Superdex 200 Increase 
5/150 GL column. The complex formation of αFITC scFv together with the FITC-DNA was proven by eluting at a lower volume 
compared to the single molecules. (B) 10 nM of FITC-ssRNA40 were incubated with different concentrations of 
αCD40.αFITCCMV (n = 3). Subsequently, fluorescence and anisotropy were measured. A concentration-dependent decrease of 
FITC fluorescence (quenching) as well as increase of anisotropy with escalating concentrations of αFITC scFv was detected.  
 
4.2. Binding and internalization 
4.2.1. Binding to primary DCs and L-428 cells 
MACs were designed to bind to the DC surface marker CD40 and thereby bringing both a TLR agonist 
and a protein-specific antigen domain to the cell. To evaluate the binding properties of the αCD40-
targeting module, the interaction of the molecules in saturating concentrations with the CD40-
expressing L-428 cell line, but also with primary iDCs and mDCs matured using a TLR8 agonist-
containing cytokine cocktail was investigated by flow cytometry-based binding studies (Figure 17). For 
this and further functional assays, αHer2 scFv or IgG1 antibodies served as non-specific binding 
controls since the L-428 cell line and DCs are Her2 negative. Figure 17A-B shows representative 
histograms of the molecules on the different cell types, Figure 17C-D displays mean MFI ratios on iDCs 
from different donors. All molecules bound specifically to CD40 on L-428 cells and DCs with higher 
binding to mDCs compared to iDCs as a result of CD40 upregulation during the maturation process. 
The insertion of the flagellin domain did not alter binding of the IgG1 format molecule on DCs and L-
428 cells. However, αCD40.Flg.αFITCCMV showed reduced MFI ratios on both cell types compared to 
αCD40.αFITCCMV maybe due to steric hindrance of flagellin and the CD40-binding site.  
A
B
0.0
0.2
0.4
0.6
0.8
1.0
N
o
rm
al
iz
e
d
 F
IT
C
 f
lu
o
re
sc
e
n
ce
0 nM
0.5 nM (20:1)
1 nM (10:1)
5 nM (2:1)
10 nM (1:1)
20 nM (1:2)
40 nM (1:4)
80 nM (1:8)
160 nM (1:16)
αFITC scFv concentration αFITC scFv concentration
1.00 1.25 1.50 1.75 2.00 2.25 2.50
0
20
40
60
80
100
Retention volume (ml)
A
28
0
 (
m
A
U
) 
n
o
rm
al
iz
ed
1.00 1.25 1.50 1.75 2.00 2.25 2.50
0
20
40
60
80
100
Retention volume (ml)
A
28
0
 (
m
A
U
) 
n
o
rm
al
iz
ed
1.00 1.25 1.50 1.75 2.00 2.25 2.50
0
20
40
60
80
100
Retention volume (ml)
A
28
0
 (
m
A
U
) 
n
o
rm
al
iz
ed
αCD40.αFITCCMVFITC-DNA αCD40.αFITCCMV + 
FITC-DNA
1.78 ml 1.67 ml 1.52 and 1.78 ml
0
50
100
150
200
250
A
n
is
o
tr
o
p
y
0nM
0.5nM (20:1)
1nM (10:1)
5nM (2:1)
10nM (1:1)
20nM (1:2)
40nM (1:4)
80nM (1:8)
16 nM (1:16)
Results 
44 
 
 
Figure 17. Binding analysis of MACs to L-428 cells and primary iDCs and mDCs. 
(A, B) Representative histograms of scFv- (A) and IgG1-based antibodies (B) to iDCs, mDCs and L-428 cells. Binding was 
detected by flow cytometry using either a FITC-conjugated αhuman Fc secondary antibody or an AF488-labeled αHis 
secondary antibody. They grey line shows non-specific stainings of the αHer2 non-specific binding controls. (C, D) Binding of 
scFv- (C) and IgG1-format (D) MACs to iDCs from different donors. Mean fluorescence intensity (MFI) ratio was calculated by 
dividing the specific antibody staining by the non-specific staining of the secondary antibody. Graphs display mean of n = 4 
different donors with SEM as error bars. 
 
4.2.2. KD determination via flow cytometry and surface plasmon resonance 
After describing the ability of MACs to bind to L-428 cells, a quantitative characterization of the binding 
strength of αCD40.αFITCCMV, αCD40.Flg.αFITCCMV, αCD40CMV and αCD40.FlgCMV was performed using 
two techniques. For the flow cytometry-based method, L-428 cells were incubated with increasing 
antibody concentrations up to saturation and binding was quantified. Subsequently, the dissociation 
constants (KD) were determined as an affinity or avidity measurement (Figure 18A and Table 16). As 
expected, a higher dissociation constant was detected for IgG1 format molecules compared to the 
scFv format probably based on bivalent binding. In correlation with the previously shown binding data, 
the fusion of flagellin domains reduced the affinity of the αCD40 scFv, but slightly lowered the 
dissociation constant for the IgG1 format molecule indicating better binding. 
As a more precise method to determine affinity including association and dissociation kinetics, an SPR 
analysis was performed for αCD40CMV and αCD40.FlgCMV (Figure 18B and Table 16). Besides detecting 
a fast on-rate and off-rate, mean KD values of 27.4 nM were obtained for αCD40CMV and 21.8 nM for 
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αCD40.FlgCMV. These values were slightly higher not only compared to the flow cytometry-based 
affinity determination, but also in comparison to the KD of this αCD40 clone published in a patent.248 
This might be explained by methodological differences of the SPR analyses. Additionally, the binding 
kinetics of the clone were investigated in an IgG2 backbone in the patent.  
 
Figure 18. KD measurements of MACs via flow cytometry and Biacore. 
(A) Concentration-dependent binding of αCD40.αFITCCMV, αCD40.Flg.αFITCCMV, αCD40CMV and αCD40.FlgCMV on L-428 cells 
was analyzed by flow cytometry. Graphs show mean values of n = 3 independent experiments with SEM as error bars. (B) 
Representative SPR profiles for αCD40CMV and αCD40.FlgCMV. Colored curves represent raw data and black curves fitted data. 
An αhuman Fc antibody was coated onto a CM5 chip to immobilize αCD40 IgG1 antibodies. As an analyte the extracellular 
domain of CD40 was injected and the concentration-dependent on- and off-rates were determined. 
 
Table 16. KD values measured by flow cytometry and SPR (Mean ± SD of n = 3 experiments) 
Molecule KD (flow cytometry) KD (SPR) 
αCD40.αFITCCMV 13.3 ± 1.3 nM n.d. 
αCD40.Flg.αFITCCMV 37.2 ± 2.1 nM n.d. 
αCD40CMV 4.9 ± 0.3 nM 27.4 ± 3.7 nM 
αCD40.FlgCMV 3.0 ± 0.2 nM 21.8 ± 1.1 nM 
n.d. = not determined 
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4.2.3. CD40-dependent internalization  
To ensure processing of the attached antigenic peptide in the endosome, MACs need to internalize 
after binding their cognate receptor. The uptake of CD40 upon bivalent binding of antibodies has 
already been investigated.116, 258 To study the intracellular translocation of this αCD40 clone and to 
detect possible differences between the IgG1- and scFv-format molecules, we incubated moDCs at 
different temperatures with directly AF594-labeled αCD40.αFITCCMV and αCD40CMV, respectively, and 
co-stained with the expected cellular compartment. As target cells both iDCs and mDCs were 
compared, as it was generally assumed that all forms of endocytosis are downregulated during the 
maturation process.259 Incubation of DCs with AF594-labeled antibodies at 4°C resulted in distinct cell 
membrane labeling, as indicated by a co-localization with HLA-DR on the cell surface (Figure 19). At 
37°C, internalization of αCD40 IgG1 and scFv molecules was detected within 1.5 hours. It turned out 
that αCD40 specifically translocated to EEA1+ early endosomal compartments, but not to late 
endosomes. With this, results by Chatterjee et al. could be confirmed.116 Furthermore, no obvious 
difference was observed between iDCs and mDCs, which is in line with published results by Platt et 
al.259 Both maturation stages equally internalized the antibodies, even if a higher CD40 surface staining 
is observed for mature DCs as expected. Therefore, in our hands, DC maturation did not obviously 
affect the level of receptor-mediated endocytosis. For all conditions only a minimal amount of non-
specific internalization occurred for the αHer2 non-specific binding controls (data not shown). 
We tested in a next step whether the FITC-labeled ssRNA40, that is derived from HIV and ligates 
intracellular TLR8, is taken up in complex with αCD40.αFITCCMV into early endosomes.164 Since the FITC 
fluorescence was shown to be quenched after interacting with the αFITC scFv, another Atto488 
fluorescence tag was added to the 3´end of the RNA. Figure 20 shows the internalization of FITC-
ssRNA40-Atto488 together with AF594-αCD40.αFITCCMV that were pre-incubated for 30 min to 
facilitate complex formation. Indeed, ssRNA40 was taken up and co-localized with the αCD40 
antibody. If pre-incubated with the αHer2.αFITCCMV non-specific binding control, less spots of 
fluorescent ssRNA40 could be found intracellularly. 
This leads to the conclusion that CD40-targeting MACs not only bound specifically to CD40 and were 
internalized upon binding into early endosomes, but they could also function as a carrier for a FITC-
labeled TLR agonist via the αFITC scFv. 
 
 
Results 
47 
 
 
Figure 19. CD40-dependent internalization of αCD40.αFITCCMV and αCD40CMV. 
Internalization of AF594-labeled αCD40.αFITCCMV scFv (A) and αCD40CMV IgG1 (B) after incubation for 1.5 h with iDCs and 
mDCs at 4°C and 37°C. At 4°C co-staining of the membrane with αHLA-DR-AF488 was performed. At 37°C the early 
endosomes were visualized by αEEA1 and late endosomes by αLAMP1 that were both detected by an AF488-labeled donkey 
αrabbit secondary antibody. All conditions were counterstained with DAPI. The scale bar represents 5 µM. The acquisition 
was performed in the laboratory of Prof. Heinrich Leonhardt. 
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Figure 20. Internalization of FITC-ssRNA40-Atto488 together with AF594-labeled αCD40.αFITCCMV and αHer2.αFITCCMV 
AF594-αCD40.αFITCCMV or the αHer2 non-specific binding control were pre-incubated for 30 min with FITC-ssRNA40-Atto488 
at 37°C, followed by incubation for 1.5 h at 4°C or 37°C on iDCs. All conditions were counterstained with DAPI und the green 
fluorescence intensity was adjusted on an equal level to compare different conditions. The scale bar represents 5 µM. The 
acquisition was performed in the laboratory of Prof. Heinrich Leonhardt. 
 
4.3. Functional characterization of MACs 
4.3.1. Induction of DC maturation 
The αCD40 antibody CP-870,893 used in thesis has been shown to bind agonistically to CD40 in its 
parental IgG2 backbone.247, 248 Therefore, we expected that maturation of DCs is already induced by 
the αCD40 binding module itself and is further enhanced by the ligation of TLRs.  
The agonistic activity of the antibody was confirmed and potential differences between scFv- and 
IgG1-format molecules investigated. For this, iDCs were incubated with αCD40.αFITCCMV and αCD40CMV 
or the respective non-specific binding controls and screened for the upregulation of maturation 
markers as well as for IL-6 secretion. TLR8 agonist-matured mDCs were included as positive control. 
The scFv-based αCD40.αFITCCMV antibody led to a significant increase in CD80, CD83 and CD86 
expression and the secretion of IL-6 compared to the αHer2 control (Figure 21A). αCD40CMV induced a 
much lower, but still significant upregulation of maturation markers on the DC surface (Figure 21B). 
Thus, without further stimulation by TLR agonists, αCD40.αFITCCMV in the scFv format shows a clear 
benefit over αCD40CMV in the IgG1 format. 
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Figure 21. Effect of αCD40.αFITCCMV scFv and αCD40CMV IgG1 on DC maturation markers and cytokine secretion. 
iDCs were incubated with αCD40.αFITCCMV (A) or αCD40CMV IgG1 (B) for 24 h. ● refers to scFv format, ○ to IgG1 format. DCs 
were analyzed based on surface expression of CD80, CD83, CD86 and HLA-DR as well as IL-6 cytokine secretion into the 
supernatant by flow cytometry. Surface markers and cytokine secretion are normalized to the control without antibody 
addition (w/o Ab). The graphs show means of n = 8 different donors with SEM as error bars. For statistical analysis, a 
Wilcoxon-signed rank test was applied. 
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Next, the stimulatory potential of fused TLR agonists was analyzed. To this end, iDCs were treated with 
αCD40.αFITCCMV with (FITC)-LPS and (FITC)-ssRNA40 or with flagellin fusion molecules (αCD40.FlgCMV 
and αCD40.Flg.αFITCCMV). Maturation marker expression and cytokine secretion induced by all 
mentioned molecules were compared with αCD40.αFITCCMV and αCD40CMV without TLR ligation and 
the respective αHer2 controls to identify potential beneficial effects of TLR fusions.  
For FITC-LPS, all maturation markers were highly upregulated and an elevated IL-6 secretion was 
measured independent of the combination with αCD40.αFITCCMV or with αHer2.αFITCCMV (Figure 22A). 
This indicates that TLR4 ligation by LPS saturates DC activation, which is not further boosted by a 
second stimulus given through the agonistic αCD40 scFv. No difference was seen between FITC-LPS 
and LPS in the low amounts of donors tested (data not shown). This could be expected as LPS binds to 
extracellular TLR4 independent of the MAC fusion. 
 
Figure 22. Effect of TLR ligation by FITC-LPS and (FITC-)ssRNA40 in combination with αCD40.αFITCCMV on DC maturation 
markers and cytokine secretion. 
iDCs were incubated with αCD40.αFITCCMV or the αHer2 control for 24 h that had been pre-incubated with equimolar 
amounts of FITC-LPS (A) and (FITC-)ssRNA40 (B) for 30 min at 37°C for complex formation. ● refers to FITC-ssRNA40, ○ to 
unlabeled ssRNA40. DCs were analyzed based on surface expression of CD80 and CD83 as well as IL-6 cytokine secretion into 
the supernatant by flow cytometry. MFI ratios of surface markers and cytokine secretion are normalized to the αHer2 control. 
The graphs show means of n = 7-9 different donors with SEM as error bars. For statistical analysis, a Wilcoxon-signed rank 
test was applied. 
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The coupling of HIV-derived FITC-ssRNA40 to αCD40.αFITCCMV induced a low, but significant increase 
in CD80 and CD83 expression as well as IL-6 secretion (Figure 22B). The addition of ssRNA40, that is 
not fused to αCD40.αFITCCMV and might be taken up independently from the antibody, did not bring a 
clear beneficial effect over αCD40.αFITCCMV. The overall stimulating effects of ssRNA40, however, were 
quite low compared to the TLR4 stimulation by LPS.  
To prove that the FITC-ssRNA40 is also effective, its functionality was tested by complexing the RNA 
with poly-L-arginine (PLA) to facilitate the endosomal transport.260 In fact, incubation of FITC-ssRNA40 
with PLA in complex with αCD40.αFITCCMV prior to adding it to the DCs increased CD80 expression in 
relation to αCD40 scFv only (Figure 23A). This uptake, however, was mostly independent of 
αCD40.αFITCCMV, since the PLA-complexed ssRNA40 in combination with the αHer2 non-specific 
binding control led to a similar DC activation. These results indicate that low effects of the ssRNA40 in 
combination with αCD40.αFITCCMV on DC maturation as seen in Figure 22B could be based on an 
insufficient uptake of the ssRNA40 by the DCs. 
A further attempt was made to facilitate the uptake of the ssRNA by cloning a HIV TAT protein-derived 
cell-penetrating peptide (CPP) sequence C-terminally of the αFITC scFv, thereby introducing a 
hydrophobic patch.246 Unfortunately, this attempt didn’t show any benefit (Figure 23B). In addition, 
these molecules were not able to induce any T cell response (data not shown). That’s why, we 
continued with the ssRNA40 to see whether the low increase in DC maturation was sufficient to 
enhance T cell responses in next experiments. 
 
Figure 23. Attempts to facilitate ssRNA40 uptake into the DCs.  
(A) (FITC-)ssRNA40 was complexed with PLA in combination with αCD40.αFITCCMV or αHer2.αFITCCMV prior to adding it to the 
cells. (B) A CPP sequence derived from the HIV TAT protein was introduced C-terminally of the αFITC scFv. ● refers to FITC-
ssRNA, ○ to unlabeled ssRNA. CD80 expression was determined by flow cytometry. MFI ratios are normalized to the αHer2 
control. The bars show means of n = 1-12 different donors with SEM as error bars. For statistical analysis, a Wilcoxon-signed 
rank test was applied.   
 
Fusing the D0/D1 domain of flagellin to αCD40.αFITCCMV induced a significant upregulation of DC 
maturation markers as well as enhanced IL-6 secretion compared to the αCD40 control (Figure 24A). 
To investigate TLR5-specific effects, the two mutations R90A and E114A were introduced (mFlg) that 
are shown to highly reduce binding to TLR5.261, 262 As expected, mutated flagellin elicited a lower DC 
maturation state compared to molecules with wild-type flagellin. The R90A single mutant was not able 
to reduce DC maturation (data not shown). In addition, αHer2.Flg.αFITCCMV increased CD80, CD83 
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expression and IL-6 secretion compared to αHer2.αFITCCMV. As the non-specific binding control itself 
was not able to bind DCs, the effects of αHer2.Flg.αFITCCMV on DC maturation indicated the stimulatory 
potential of flagellin that was activating DCs to a similar extent as the αCD40.αFITCCMV. In line with the 
scFv results, flagellin fusion to αCD40CMV upregulated surface maturation markers and enhanced IL-6 
secretion, which was lowered by mutating flagellin (Figure 24B). To investigate whether the genetic 
fusion of αCD40CMV and flagellin maintains functionalities of both fusion partners, we compared the 
activity of αCD40.FlgCMV to co-administered Fc.Flg and αCD40CMV (Figure 24C). Even if a difference 
between the two variants was seen for the αHer2 control molecule, treatment with αCD40.FlgCMV and 
also the combination of Fc.Flg and αCD40CMV led to similar DC maturation states, as reflected by CD80 
and CD83 expression. This indicates that fusion of flagellin to αCD40CMV does not greatly affect its 
interplay with TLR5 and that neither antibody nor flagellin integrity is impaired. 
The flagellin fusion molecules were also tested in the scFv format without the αFITC scFv as this would 
be redundant in this molecule. In this format, the flagellin domain and the CMV-specific peptide were 
connected by either a G4S or a (G4S)4 linker. The αCD40 module was also exchanged by a different DC-
targeting binder, namely αDec205, that is not activating the DCs itself. In all of the tested fusion 
molecules, flagellin-specific TLR5 ligation and DC maturation was achieved as predicted and the 
flagellin mutant abolished the activating effects (data not shown). However, none of the molecules 
was able to elicit a T cell response maybe due to suboptimal uptake and therefore processing of the 
peptide (data not shown). Hence, only the most promising flagellin fusion candidates 
αCD40.Flg.αFITCCMV and αCD40.FlgCMV were investigated further. 
In summary, FITC-LPS highly activated DCs. This was mainly independent of the DC-targeting antibody, 
since LPS binds TLR4 on the DC surface without the need of being targeted to the DC by interacting 
with αCD40.αFITCCMV in vitro. TLR8 ligation by FITC-ssRNA40 in combination with αCD40.αFITCCMV 
induced a slightly higher DC maturation compared to uncoupled ssRNA40 due to targeted delivery. 
However, the beneficial effect of TLR8 ligation compared to αCD40.αFITCCMV without TLR stimulation 
was low. In further experiments using complexed ssRNA, it turned out that the uptake of FITC-ssRNA40 
in combination with the αFITC scFv was not optimal, even if microscopic investigation of ssRNA40 
internalization looked promising. The fusion of the TLR5-binding domain of flagellin to the non-
targeting αHer2 scFv or IgG1 molecule already activated DCs significantly, which was even further 
boosted by combining it with the DC-targeting αCD40 binder. The flagellin mutant with impaired TLR5 
binding diminished these effects, which indicates a TLR5-specific DC activation mechanism. 
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Figure 24. Effect of TLR5 ligation on DC maturation. 
iDCs were incubated with αCD40.Flg.αFITCCMV (A) or αCD40.FlgCMV (B) or their controls without flagellin or mFlg as well as 
the αHer2 non-specific binding controls. ● refers to scFv format, ○ to IgG1 format. (C) Difference between the genetic fusion 
of flagellin and the co-administration of the DC-targeting antibody and Fc.Flg. iDCs were incubated with the flagellin fusion 
molecule (αCD40.FlgCMV) or the combination of αCD40CMV and Fc.Flg or the respective controls. ● refers to flagellin fusion 
molecules, ○ to the combination of αCD40/Her2 and Fc.Flg. Surface maturation marker expression and secretion of IL-6 was 
determined by flow cytometry. MFI ratios were normalized to the non-specific binding control. The graphs show means of n 
= 10 different donors with SEM as error bars. For statistical analysis, a Wilcoxon-signed rank test was applied.  
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4.3.2. Interaction with TLR5 
As the genetic fusion of flagellin to a DC-targeting antibody construct might interfere with TLR5 
interaction, binding to its receptor and the induction of downstream signaling was analyzed. First, 
flagellin-induced DC maturation was investigated with and without the presence of an IgA2 αTLR5-
blocking and neutralizing antibody. To this end, iDCs were preincubated with either the blocking 
antibody or the isotype control followed by the addition of flagellin fusion molecules or the respective 
mutants and controls. Figure 25 shows that the flagellin-induced upregulation of DC maturation 
markers was greatly diminished by the presence of the αTLR5 antibody, but not by the isotype control. 
Thus, the TLR5 interaction was necessary for the stimulation of DC maturation by αCD40.Flg.αFITCCMV, 
αCD40.FlgCMV and Fc.Flg. 
 
Figure 25. Flagellin-induced DC maturation in presence of an αTLR5-blocking antibody.  
iDCs were pre-treated with either an IgA2 αTLR5-blocking antibody or the IgA2 isotype control with subsequent 
administration of flagellin fusion molecules or controls as indicated. Filled bars refer to scFv format, open bars to IgG1 format. 
CD80 and CD83 expression was measured on the DC surface by flow cytometry. MFI ratios of surface markers are normalized 
to the non-specific binding control. The bars show means of n = 3 different donors with SEM as error bars. 
 
Second, the activation of TLR5 downstream signaling processes by flagellin fusion molecules was 
studied. A hTLR5-HEK293 reporter cell line, transiently transfected with human full-length TLR5, was 
incubated with abovementioned molecules and signal transduction was analyzed based on IL-8 
secretion. As expected, αCD40.FlgCMV and Fc.Flg induced TLR5 signaling in a similar extent, whereas 
αCD40.mFlg.αFITCCMV and αCD40.mFlgCMV did not (Figure 26). Interestingly, αCD40.Flg.αFITCCMV 
showed a lower IL-8 secretion compared to the IgG1 fusion. 
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Figure 26. Induction of TLR5 signaling by flagellin fusion molecules. 
HEK293-T cells transiently transfected with hTLR5 (hTLR5-HEK293) were incubated with αCD40.FlgCMV, αCD40.mFlgCMV or 
Fc.Flg or the scFv format flagellin fusions. Filled bars refer to scFv format, open bars to IgG1 format. IL-8 secretion into the 
supernatants was determined by ELISA. Graph displays mean values of biological duplicates each measured in triplicates. 
This experiment was performed in the laboratory of Prof. Christine Josenhans. 
 
Taken together, the data show that αCD40.αFITC.FlgCMV and αCD40.FlgCMV molecules enhanced DC 
maturation by specifically interacting with TLR5 and were able to induce downstream signaling 
processes. 
 
4.3.3. MAC-mediated CMVNLV-specific T cell activation and proliferation  
The main goal of this thesis was to generate a DC-based vaccine that specifically brings a peptide as 
payload to the DC, simultaneously activates an adjacent TLR and thereby induces an efficient peptide-
specific T cell response. Here, the ability of αCD40.αFITCCMV and αCD40CMV to induce T cell activation 
and proliferation was characterized in allogeneic as well as autologous DC–T cell co-culture 
experiments (Figure 27). The modulation of the T cell response by the addition of different TLR-ligating 
domains was further investigated. 
 
Figure 27. Experimental setup of DCs co-cultivated with autologous non-adherent PBMCs (NACs) or allogeneic expanded 
CMVNLV-specific T cells with readouts for T cell activation and proliferation.  
 
First, we addressed the question of whether the CMV-specific peptide fused to αCD40 is correctly 
processed into the epitope sequence NLVPMVATV (CMVNLV) and subsequently cross-presented on the 
DC surface via MHC I. iDCs and mDCs from HLA-A*02:01+ donors that were pre-loaded with 
αCD40.αFITCCMV, the αHer2 control (Figure 28A) or with the respective IgG1 format molecules (Figure 
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28B) were cultivated with allogeneic expanded CMVNLV-specific CD8+ T cells. To rule out the possibility 
of T cell activation triggered by αCD40-mediated DC maturation and to confirm antigen specificity, an 
αCD40 antibody coupled with a non-stimulating peptide was included as a control (αCD40.αFITCmNPM1 
and αCD40mNPM1, vide infra). T cell functionality was validated by pulsing the DCs with the already 
processed CMVNLV peptide. Subsequently, T cell activation was measured by intracellular IFN-γ and 
TNF-α staining of CD8+ T cells via flow cytometry. Independent of the molecule formats and the DC 
maturation state, αCD40.αFITCCMV- and αCD40CMV-loaded iDCs and mDCs elicited significantly higher 
T cell activation compared to those treated with the αCD40 and αHer2 controls. As expected, the 
highest secretion of proinflammatory cytokines was achieved for the CMVNLV-peptide pulsed DCs as a 
positive control that were loaded with the peptide from the outside without requiring internalization 
and processing. This proved the specificity of the T cell population. Notably, the αHer2 non-specific 
binding controls induced a low amount of non-specific T cell activation especially if loaded on mDCs. 
 
Figure 28. Co-culture of allogeneic CMVNLV-specific T cells and HLA-A*02:01+ iDCs or mDCs pre-incubated with MACs or 
peptide. 
DCs were loaded with αCD40.αFITCCMV scFv (A) and αCD40CMV IgG1 (B), αCD40 conjugated to a control peptide 
(αCD40.αFITCmNPM1 or αCD40mNPM1), the αHer2 controls or the processed CMVNLV peptide prior to starting the cultivation. As 
a readout for T cell activation, IFN-γ- and TNF-α-producing CD8+ T cells were quantified by flow cytometry. ● refers to scFv 
format, ○ to IgG1 format. T cell activation is normalized to w/o Ab. Bars show means of n = 8-12 donors with SEM as error 
bars. For statistical analysis, a Wilcoxon-signed rank test was applied. 
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We next analyzed, whether T cells were stimulated sufficiently to proliferate after encountering 
CMVNLV-presenting DCs (Figure 29). The non-adherent PBMC fraction (NACs) of an HLA-A*02:01+ 
donor with previous CMV infection was co-cultured with autologous DCs. The DCs were pre-loaded 
with the molecules as described for the allogeneic setting. CMVNLV-specific dextramer staining was 
performed to determine the number of expanded CMVNLV-specific T cells. In line with the results 
obtained for allogeneic co-cultures, αCD40.αFITCCMV- and αCD40CMV-loaded iDCs and mDCs led to a 
significantly higher CMVNLV-specific T cell proliferation compared to the control molecules in the 
autologous setting. Again, mDCs loaded with the αHer2 non-specific binding controls triggered some 
amount of T cell proliferation. T cells proliferated the most after interaction with CMVNLV-loaded DCs. 
Thus, the αCD40 IgG1 and the scFv format molecules were able to induce a T cell response, but 
αCD40.αFITCCMV was more potent in delivering the peptide to DCs. 
Taken together, targeting CMV peptides to DCs via αCD40 leads to correct antigen processing and 
cross-presentation and induces activation and proliferation of antigen-specific T cells. Consistent with 
previous results, this validates the targeting approach and confirms a functional molecule design. 
 
Figure 29. Co-culture of autologous NACs of an HLA-A*02:01+ and CMV+ donor and iDCs or mDCs pre-incubated with MACs 
or peptide.  
DCs were loaded with αCD40.αFITCCMV scFv (A) and αCD40CMV IgG1 (B), the αHer2 controls or the processed CMVNLV peptide 
prior to starting the cultivation. T cell proliferation was determined by CMVNLV-specific dextramer staining of CD8+ T cells and 
measured by flow cytometry. ● refers to scFv format, ○ to IgG1 format. T cell proliferation is normalized to w/o Ab. Bars 
show mean values of n = 10 donors with SEM as error bars. For statistical analysis, a Wilcoxon-signed rank test was applied. 
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In the following, different TLR agonists as adjuvants were fused to αCD40.αFITCCMV and αCD40CMV to 
identify which antibody–adjuvant combination is most beneficial for cross-presentation and T cell 
activation in vitro. Autologous and allogeneic co-culture experiments were performed as previously 
described. In addition to the molecules without TLR ligation, iDCs were pre-incubated with antibody–
adjuvant fusion molecules to identify the impact of TLR stimulation on T cell responses and to 
investigate potential differences between TLR agonists.  
In contrast to results expected from the DC maturation data, the combination of αCD40.αFITCCMV with 
FITC-LPS to target TLR4 on the DC surface led to a slight reduction of the T cell response compared to 
αCD40.αFITCCMV as indicated by a diminished cross-presentation and T cell proliferation (Figure 30A).  
Intracellular TLR8 was ligated by ssRNA40. In this setting, the fusion of the RNA to the antibody is 
exceptionally important for in vitro experiments, as this directs the ssRNA40 specifically to early 
endosomal compartments as shown by microscopy. The combination of αCD40.αFITCCMV with FITC-
ssRNA40 induced a significantly higher T cell proliferation compared to αCD40.αFITCCMV, which could 
not be achieved by uncoupled ssRNA40 (Figure 30B). By using allogeneic CMVNLV-specific cells as T cell 
source, a slight, but not significant increase of T cell activation could be detected as well. This was 
surprising as previous data showed that FITC-ssRNA40 was only able to induce a minimal amount of 
DC maturation due to an inefficient uptake into the endosomes. However, the activity of ssRNA40 
seems to be enough to induce a T cell response. As the RNA uptake could be boosted by the 
complexation with PLA, which leads to intracellular translocation of the ssRNA40 independent of the 
antibody, the combination of PLA, ssRNA40 and antibody was also tested in the T cell readouts (Figure 
30C). Surprisingly, if higher amounts of ssRNA40 were present in the endosome to interact with TLR8, 
the beneficial effect of the ssRNA40 was lost since αCD40.αFITCCMV plus PLA-complexed FITC-ssRNA40 
did not induce a higher T cell response compared to αCD40.αFITCCMV.  
Extracellular TLR5 was ligated by fusing flagellin either C-terminally of an αCD40 scFv 
(αCD40.Flg.αFITCCMV) or to the αCD40 heavy chain (αCD40.FlgCMV). Even if αCD40.Flg.αFITCCMV and 
αCD40.FlgCMV were able to induce similar DC maturation states, functional T cell assays revealed 
differences between both formats. When conjugated to the αCD40 scFv antibody, the flagellin domain 
impaired the T cell response (Figure 31A). However, αCD40.FlgCMV in the IgG1 format significantly 
enhanced cross-presentation and T cell proliferation compared to αCD40CMV that was dampened by 
the flagellin mutant (Figure 31B). In line with the maturation data, no difference in T cell response was 
observed between αCD40.FlgCMV and co-administered αCD40CMV and Fc.Flg highlighting that coupling 
of the activating flagellin domain to the DC-targeting αCD40 antibody does not alter its functionality 
(Figure 31C).  
Taken together, αCD40.FlgCMV was rated as the most promising molecule that combined the benefit in 
peptide cross-presentation and T cell activation together with a potent DC maturing activity in one 
molecule. 
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Figure 30. Co-cultures of allogeneic or autologous T cells and iDCs loaded with αCD40.αFITCCMV and simultaneous co-
administration of TLR4 and 8 ligands. 
Autologous and allogeneic co-cultures were performed as previously described. iDCs were incubated with αCD40.αFITCCMV 
or the non-specific binding control and stimulated by FITC-LPS (A), (FITC-)ssRNA40 (B) or by PLA-complexed (FITC-)ssRNA40 
(C). T cell proliferation was analyzed by CMVNLV-specific dextramer staining of CD8+ T cells and activated T cells were 
quantified via intracellular IFN-γ and TNF-α staining of CD8+ T cells, both measured by flow cytometry. The T cell response is 
normalized to the αHer2 control. ● refers to FITC-ssRNA, ○ to unlabeled ssRNA. Graphs indicate means of n = 5-10 donors 
with SEM as error bars. For statistical analysis, a Wilcoxon-signed rank test was applied.  
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Figure 31. Co-cultures of allogeneic or autologous T cells and iDCs loaded with αCD40.αFITCCMV or αCD40CMV with and 
without fusion of the flagellin D0/D1 domain. 
Autologous and allogeneic co-cultures were performed as previously described. (A, B) iDCs were incubated with 
αCD40.Flg.αFITCCMV (A) or αCD40.FlgCMV (B) for TLR5 activation or their controls without flagellin or mFlg as well as the αHer2 
non-specific binding controls. ● refers to scFv format, ○ to IgG1 format. (C) Difference between genetic fusion of flagellin 
and co-administration of DC-targeting antibody and Fc.Flg. iDCs were incubated with the flagellin fusion molecule 
(αCD40.FlgCMV) or the combination of αCD40CMV with Fc.Flg or the respective controls. ● refers to flagellin fusion molecules, 
○ to the combination of αCD40/Her2CMV with Fc.Flg. T cell proliferation was analyzed by CMVNLV-specific dextramer staining 
of CD8+ T cells and activated T cells were quantified via intracellular IFN-γ and TNF-α staining of CD8+ T cells, both measured 
by flow cytometry. The T cell response is normalized to the αHer2 control. Graphs show means of n = 2-10 donors with SEM 
as error bars. For statistical analysis, a Wilcoxon-signed rank test was applied. 
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4.3.4. MAC-mediated mNPM1CLA-specific T cell activation 
The before-mentioned experiments served as an important groundwork, on which the development 
of a novel therapeutic molecule to treat AML could be based. In the following part of the thesis, the 
vaccine concept was replicated in the leukemia setting by replacing the CMV-specific peptide with an 
mNPM1-derived neoantigen. The functionality of αCD40.αFITCmNPM1 scFv and αCD40mNPM1 IgG1 was 
proven by verifying that the fused mNPM1277–298 sequence was correctly processed and cross-
presented as CLAVEEVSL (mNPM1CLA) on HLA-A*02:01.  
For co-culture experiments, CD8+ T cells were used that were transduced with a TCR recognizing this 
antigen in the context of HLA-A*02:01. These showed reactivity against HLA-A*02:01+ and mNPM1+ 
AML cell lines and primary patient cells.224 The mNPM1CLA-specific T cell population was co-cultured 
with DCs that had been pre-incubated with αCD40.αFITCmNPM1, the αHer2 control or with an αCD40 
conjugated to a control peptide (αCD40.αFITCCMV). T cell functionality was validated using mNPM1CLA-
pulsed DCs. In fact, the mNPM1CLA-specific T cells recognized the presented epitope on 
αCD40.αFITCmNPM1-incubated DCs as detected by IFN-γ and TNF-α secretion (Figure 32A). Pulsing of 
DCs with the processed mNPM1CLA peptide as positive control led to the highest response and 
confirmed the specificity of the T cells. When the same experiment was performed using IgG1 format 
molecules, DCs incubated with αCD40mNPM1 also successfully cross-presented the mNPM1CLA peptide 
on MHC I and led to a higher T cell activation compared to the negative controls (Figure 32B). In line 
with the findings for the CMV setting, the αCD40mNPM1 was inferior to αCD40.αFITCmNPM1 in the scFv 
format regarding T cell activation. 
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Figure 32.  Co-culture of allogeneic mNPM1CLA-specific T cells and HLA-A*02:01+ iDCs and mDCs pre-incubated with MACs 
or peptide. 
DCs were loaded with αCD40.αFITCmNPM1 scFv (A) and αCD40mNPM1 IgG1 (B), αCD40 conjugated to a control peptide 
(αCD40.αFITCCMV or αCD40CMV), the αHer2 controls or the processed mNPM1CLA peptide prior to starting the cultivation. As 
a readout for T cell activation, IFN-γ- and TNF-α-producing CD8+ T cells were quantified by flow cytometry. In B, 
representative flow cytometry dot plots of co-cultures of T cells and iDCs are shown. ● refers to scFv format, ○ to IgG1 format. 
T cell activation is normalized to w/o Ab. Bars represent means of n = 10 donors with SEM as error bars. For statistical analysis, 
a Wilcoxon-signed rank test was applied. 
 
As αCD40.FlgCMV was the most promising molecule in previous experiments with the flagellin domain 
enhancing both DC maturation and cross-presentation to T cells, its stimulatory potential was also 
investigated in the leukemia setting. For this purpose, iDCs are loaded with αCD40mNPM1, 
αCD40.FlgmNPM1 or αCD40.mFlgmNPM1 as well as the respective αHer2 controls and cultivated with 
mNPM1CLA-specific T cells (Figure 33). Again, fusing flagellin to αCD40mNPM1 significantly enhanced the 
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T cell response compared to the control without flagellin. The beneficial effect of the TLR5 ligation 
could be reversed by the insertion of R90A/E114A mutations into the flagellin domain. 
 
Figure 33. Co-culture of allogeneic mNPM1CLA-specific T cells and iDCs loaded with αCD40mNPM1 with and without flagellin 
fusion to ligate TLR5. 
Allogeneic co-cultures were performed as previously described. iDCs were incubated with αCD40mNPM1, αCD40.FlgmNPM1 or 
αCD40.mFlgmNPM1 as well as the respective αHer2 controls. Activated T cells were quantified by counting IFN-γ- and TNF-α- 
producing CD8+ T cells by flow cytometry. (A) Representative flow cytometry dot plots for one donor are shown. (B) 
Summarized T cell activation data normalized to the non-specific binding control. Bars indicate means of n = 10 donors with 
SEM as error bars. For statistical analysis, a Wilcoxon-signed rank test was applied. 
 
Taken together, targeting a mNPM1-derived peptide to DCs by conjugation to an αCD40 scFv and IgG1 
antibody led to an efficient mNPM1CLA-specific T cell response. Fusion of the TLR5 agonist flagellin to 
αCD40mNPM1 was able to stimulate DCs thereby enhancing cross-presentation of conjugated 
neoantigens to CD8+ T cells. These results confirm the functionality of the molecule in vitro and 
motivate for further evaluation in vivo to prove it a promising treatment option for AML. 
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5. Discussion 
5.1. Rationale for MACs 
DC vaccination strategies are widely considered as a powerful tool in immunotherapy of cancer and 
other diseases. Numerous clinical studies utilizing the initially developed ex vivo DC vaccination have 
been employed in different cancer entities and demonstrated safety and immunogenicity of the 
vaccines.61 At the same time, these clinical trials have often demonstrated a poor efficacy.263 One of 
the major factors restricting in vivo potency is the inefficient migration of administered DCs to the 
lymph node, wherein DCs activate antigen-specific T cells. The ex vivo DC generation process is also 
challenged by the expensive and labor-intensive GMP production that is difficult to standardize as the 
vaccines need to be generated for each patient individually. Therefore, in vivo targeting of DCs was 
more recently being exploited. This allows for large-scale vaccine production since it can be applied to 
a larger patient cohort. More importantly, it also exhibits biological advantages as it exploits the 
intrinsic migratory capacity of DCs and directly activates natural DC subsets at multiple sites in vivo, 
thereby producing a more physiological DC maturation.80, 92, 264 Even if clinical data are still rare, in vivo 
vaccination is considered as a promising strategy for eliciting strong and lasting T cell response against 
intracellular pathogens and cancer.263, 265 
Common to all vaccination approaches, DCs targeted by the antigen need to gain optimal T cell 
stimulating capacities. It is well known that immature DCs tend to induce tolerogenic responses at 
steady state while in the presence of adjuvants, maturation markers are upregulated and tolerance 
induction is abrogated.126 Thus, to augment therapeutic efficacy, peptide-based cancer vaccines and 
DC-targeting antibodies are usually co-administered with adjuvants such as TLR agonists in a 
uncoupled manner.266 Soluble adjuvants, however, allow for the activation of immune cells that do 
not present the delivered antigen, which implicates the risk of counterproductive side effects such as 
cytokine release or autoimmunity.132, 133 To improve the safety profiles and to reduce the necessary 
dose, vaccines have been generated that combine the antigen and adjuvant in one delivery system or 
even in one molecule. Approaches such as exosome-based tumor antigens–adjuvant co-delivery 
systems or polymeric nanoparticles encapsulating both peptides and TLR agonists have been 
developed.133, 267, 268 Alternatively, the adjuvant can be also directly fused to the peptide vaccine or 
DC-targeting antibody.134, 242-244, 269 Targeted delivery of TLR ligands was not only associated with 
reduced serum cytokine release and related toxicity, but also reduced their dose requirement by 100-
fold.133 Furthermore, co-delivery of antigen and adjuvant into the same APC resulted in superior cross-
presentation and peptide-specific T cell activation compared to separate molecule administration in 
vivo.133, 134, 242-244 This implicates that direct coupling of the adjuvant increases vaccine efficacy while 
providing highest specificity of targeting and DC activation. In parallel, it allows the reduction of the 
adjuvant dose making side effects less likely.134 
The benefits observed for both in vivo DC vaccination and for antigen-adjuvant conjugates served as 
rationales for this project. We generated multifunctional antibody constructs that combine in vivo 
targeting of antigens to DCs and stimulation by TLR agonists in one molecule. CD40 was selected as 
DC surface receptor to be targeted by either IgG1- or scFv-based constructs that exhibit themselves 
adjuvant activity. To further amplify the system, the stimulation by agonistic αCD40 constructs was 
combined with additional activating signals delivered by different TLR agonists (LPS, flagellin or 
ssRNA40). By using a CMV-specific antigen domain for proof-of-principle studies, the best molecule 
combination that elicited highest DC maturation with correlating T cell response was identified, 
namely αCD40.FlgCMV in the IgG1 format. This molecule was further tested in a tumor setting by 
delivering the mNPM1-derived neoantigen to DCs aiming to develop a potent AML-directed DC 
vaccine. The novelty of the therapeutically relevant and most promising candidate molecule 
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αCD40.FlgmNPM1 is not only the combination of DC-targeting of antigens and the adjuvant in one 
molecule, but also the use of mNPM1 as an AML-specific neoantigen in a vaccination concept. This is 
the first study to investigate neoantigen delivery to a DC-targeting antibody, which was motivated by 
the encouraging results from clinical trials that investigated personalized neoantigen vaccines in other 
cancer entities.72-75 Despite their even greater impact, data on therapies employing shared neoantigen 
vaccines are sparely available.77, 78 Since mNPM1 is a shared neoantigen of 30% of AML patients, the 
groundwork for the development of a “off-the-shelf” vaccine to treat AML should be laid with the 
mNPM1-directed vaccine. 
 
5.2. Comparative analysis of MACs activating different TLRs 
MACs were generated by fusing various TLR agonists to a peptide-coupled DC-targeting antibody 
construct of either an αCD40 Fc-silenced IgG1 or scFv format. The TLR4 agonist LPS and TLR8 agonist 
ssRNA40 were linked via an αFITC scFv to αCD40.αFITCCMV, whereas the TLR5 agonist flagellin was 
genetically fused to αCD40 IgG1 (αCD40.FlgCMV) and scFv (αCD40.Flg.αFITCCMV). A comparative analysis 
of the molecules was performed to rate them based on protein yield, the ability to induce DC 
maturation, T cell activation and proliferation as well as the innovation and impact (Figure 34). 
 
 
Figure 34. Comparative analysis of MACs activating different TLRs. 
 
Concerning protein yield, the αCD40 antibody constructs without flagellin fusion were advantageous 
over αCD40.Flg.αFITCCMV and αCD40.FlgCMV and could be expressed in reasonable amounts. However, 
genetic fusion of the flagellin domain reduced expression yields by approximately 2-fold in the scFv 
format and by 6-fold in the IgG1 format. 
Next, the induction of DC maturation by MACs with or without TLR agonists was investigated. The 
αCD40 variable regions used in these studies have been derived from CP-870,893 (clone 21.4.1) that 
was shown to bind agonistically to CD40 in its original IgG2 format.247, 248 αCD40.αFITCCMV in the scFv 
format showed a high agonistic potential. Surprisingly, the αCD40CMV in the IgG1 format displayed a 
minor activating potential as shown by a low, but still significant upregulation of maturation markers. 
The agonistic activity of αCD40 antibodies, but also of other agonistic receptor-engaging antibodies, 
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is in general dependent on their potential to crosslink CD40. It has long been believed to rely 
predominantly on crosslinking by the inhibitory FcγRIIb to deliver their activity.270, 271 Clone CP-870,893 
of the IgG2 isotype just reveals low affinity binding to FcγRs and still exhibits immune activating 
potential. White et al. postulated that the agonistic activity was solely mediated by unique hinge 
properties of the IgG2 subclass.272 This could be disproven two years later, as CP-870,893 in the IgG1 
format with a different hinge region showed even higher immune activation, while the activity of IgG1 
was completely abolished by the Fc-silencing N297A mutation.273 Both publications indicated that the 
potency of agonistic CD40 antibodies can be influenced by the level of Fc crosslinking and by different 
hinge regions. However, the CD40 epitope recognized and the strength of the signal achieved seem to 
be the more important determinants.274 In line with this, it was shown in this thesis that the 
αCD40.αFITCCMV was able to highly activate DCs even without an Fc portion present. The exact 
mechanisms that explain, why the scFv format was even more efficient in immune cell activation 
compared to the Fc-silenced IgG1 format, remains elusive, but both antibody formats seem to bind in 
a different manner to CD40. Importantly, all TLR agonists were able to upregulate DC maturation 
markers and enhanced IL-6 secretion. Flagellin and LPS were similarly able to stimulate DCs. The 
lowest DC maturating activity was seen for the ssRNA40 probably due to an inefficient uptake of the 
FITC-ssRNA in combination with αCD40.αFITCCMV. When the RNA was complexed with PLA to facilitate 
the endosomal transport, ssRNA40 highly increased in DC maturation. 
We further assessed the ability of antibody-peptide conjugates of different formats to induce T cell 
activation and proliferation without an adjuvant. Our in vitro studies have shown that 
αCD40.αFITCCMV- and αCD40.αFITCmNPM1-loaded DCs more efficiently cross-presented the peptides 
and triggered T cell responses compared to αCD40CMV and αCD40mNPM1. This indicated that the scFv 
format was more potent if used without additional stimulation, probably because of a higher intrinsic 
agonistic activity. When the T cell responses with TLR ligation were explored in a following step, it 
turned out that an increased DC maturation does not automatically correlate with enhanced cross-
presentation and T cell activation. PLA-complexed FITC-ssRNA40, that highly activated DCs, combined 
with αCD40.αFITCCMV was not able to boost T cell responses. FITC-LPS resulted in a slightly lower T cell 
activation and proliferation compared to αCD40.αFITCCMV, although TLR4 ligation considerably 
upregulated DC maturation markers. The fusion of flagellin to the scFv format MAC 
(αCD40.Flg.αFITCCMV) even led to a significantly decreased T cell proliferation compared to 
αCD40.αFITCCMV. In contrast, the combination of FITC-ssRNA40 and αCD40.αFITCCMV did not greatly 
enhance DC maturation and T cell activation, but significantly increased T cell proliferation compared 
to αCD40.αFITCCMV alone as well as with addition of uncoupled ssRNA40. Importantly, the 
αCD40.FlgCMV MAC in the IgG1 format both upregulated DC maturation markers and enhanced the T 
cell response compared to αCD40CMV. 
In general, DC maturation is characterized by an enhancement in antigen processing and (cross-
)presentation for example by the increased synthesis and surface levels of MHC class I and II 
molecules.275, 276 DC maturation further stimulates T cells, which is mediated by the upregulation of 
co-stimulatory surface molecules and the secretion of proinflammatory cytokines.277 However, the 
functional capability of DCs to induce T cell activation does not always directly correlate with common 
maturation markers, for example because Tregs use some of the same signaling pathways including 
CD80/CD86.278-280 In addition, it was generally presumed that DC maturation downregulates the 
potential of DCs to take up antigens and all forms of endocytosis. Platt et al. reported that DCs indeed 
shut down micropinocytosis responsible for the non-selective uptake of extracellular material, but 
they continue to accumulate antigens especially by receptor-mediated endocytosis and 
phagocytosis.259 This has also been seen in our microscopy analysis showing that iDCs and mDCs highly 
internalized antibodies and that the DC maturation state did not obviously affect the level of receptor-
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mediated endocytosis. Still, the observations that TLR activation induces DC maturation while 
occasionally impairing T cell activation and proliferation might be a combinatorial effect of reduced 
antigen accumulation and cross-presentation as well as the induction of Tregs that compromise CD8+ 
T cell responses. The latter should not have a high influence in allogeneic co-cultures of DCs and 
expanded peptide-specific T cells that mostly consist of a CD8+ population. But Treg triggering might 
be a problem in the autologous setting using NACs, even if this could not be observed in some initial 
experiments (data not shown). In addition, overactivation of DCs that leads to activation-induced cell 
death (AICD), as for example described after LPS challenge, might limit the ability to take up antigens 
and stimulate T cells.281, 282 Especially the combination of the highly activating αCD40 scFv format with 
other TLR ligands might have been an overkill. Hence, it would have been interesting to couple FITC-
LPS to an αCD40 IgG1 antibodies with αFITC scFvs fused to the light chains and to investigate LPS 
induced T cell response in combination with a low maturating αCD40 format. However, since impaired 
T cell activation as response to highly matured DCs is barely described in the literature, these results 
would maybe not be translatable into in vivo systems and would clinically not have any significance.  
Not only differences in DC maturation might have affected the internalization process of MACs and 
therefore the availability of processed peptides. The finding that αCD40.Flg.αFITCCMV-loaded iDCs less 
efficiently interacted with T cells might be the result of the diminished binding to DCs and therefore 
impaired internalization compared to αCD40.αFITCCMV, which would need to be proven by microscopy. 
Also, the interaction of flagellin and LPS with surface TLRs might disturb antibody internalization and 
lead to reduced T cell activation. This is, however, contradicted by the beneficial effects observed for 
flagellin fusion to the αCD40CMV IgG1 and by the fact that ssRNA40 in combination with PLA targeting 
intracellular TLR8 showed the same inhibitory trend. 
To sum up the in vitro findings, all MACs elicited DC maturation but differed in their properties to 
induce T cell activation and proliferation. The flagellin fusion molecule αCD40.FlgCMV was the only MAC 
that showed consistent results in DC maturation and T cell response. It is also biochemically and 
clinically the most relevant molecule due to the genetic flagellin fusion and the stable interaction 
between TLR agonist and antibody. Together with the novelty of the format, αCD40.FlgCMV is 
considered as the most promising candidate to be further investigated. 
 
5.3. Advantages and limitations 
As mentioned before, the constructs developed in this thesis offer important benefits compared to 
conventional ex vivo DC strategies and compared to therapeutic regiments where the adjuvant and 
the antibody–antigen conjugate are co-administered instead of being fused. 
All MACs target CD40 on the DC surface. The delivery of antigens to DCs by CD40-targeting antibodies 
was shown to be more efficient in eliciting MHC I cross-presentation and to induce the highest levels 
of CD8+ T cell responses in comparison to other receptors.116, 283, 284 Chatterjee et al. demonstrated 
that this effect was predominantly promoted by the intracellular trafficking pathway.116 αCD40 
antibodies not only elicit DC-targeting function, but also induce CD40 signaling in the case of an 
agonistic binder, such as the one used in this work. As this delivers an intrinsic co-stimulatory signal 
to DCs, the use of αCD40 antibodies might also be advantageous over antibodies directed against 
other endocytic receptors. However, especially the context of immune cell activation, agonistic αCD40 
binders including the one used in this studies have a somewhat bad reputation. Being initially 
developed to suppress tumor growth as a monotherapy for different cancer entities with promising 
antitumor effects, agonistic αCD40 antibodies have been also used for vaccination approaches.285-287 
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In combination with fused or soluble antigens, they exhibited strong and promising adjuvant activity 
even at low doses.114 However, in clinics, severe treatment-related adverse events such as cytokine 
release syndrome and hepatotoxicity have been reported for the parental antibody version CP-
870,893 limiting the dosage and the treatment.247, 285 This antibody also induced chronic B-cell 
activation associated with diminished circulating T cell numbers in some patients, that was also 
observed in mouse studies with different αCD40 clones.288-290 This might have resulted from AICD, 
since CD40 is also expressed on activated T cells.291 In addition, hyper immune stimulation by CD40 
agonists also poses the risk of T cell anergy, which might be particularly detrimental if those agonistic 
αCD40 antibodies are used in the context of DC vaccines.289 As a consequence, the dose needs to be 
tightly titrated or the affinity to CD40 adjusted to reduce systemic toxicity induced by overactivation 
and to maintain the vaccine efficacy. In our experiments, αCD40CMV in the Fc-silenced IgG1 format 
displayed only low agonistic activity, whereas αCD40.αFITCCMV with a αCD40 scFv upregulated DC 
maturation markers more strongly. Especially if combined with another TLR ligating stimulus, the 
αCD40CMV is presumably beneficial over the scFv format in regard to adverse events. It might combine 
the advantage of low intrinsic agonistic activity with the benefit of targeting antigens to CD40 
concerning cross-presentation and T cell activation. However, if used without additional stimulation 
by TLR agonists, the scFv format was more potent.  
The two formats reveal additional differences. Due to their smaller size, scFvs enter into the tissues, 
where targeted iDCs are resident, more easily compared to antibodies in the IgG1 format.  Molecules 
of smaller size are faster cleared from the plasma and reveal shorter half-lives.122 Importantly, as scFvs 
lack Fc domains and the αCD40 IgG1 displays a effector-silent Fc region, both formats do not bind to 
Fcγ receptors and provide therefore CD40-specific antigen delivery by reducing non-specific uptake of 
antigens.123 The PGLALA-mutated αCD40 IgG1 is still able to bind FcRn resulting in the same favourable 
pharmacokinetic profile as wild-type IgG1 molecules.124 
Regarding cell selectivity, αCD40 antibodies would target not only DCs but also other CD40-expressing 
cells including predominantly B cells, monocytes, macrophages, hematopoietic progenitors, 
fibroblasts, endothelial and epithelial cells.118-120 To achieve DC-specific targeting and to overcome 
problems related to potential antigen sinks, other groups have shown that the administration route 
plays an important role. In particular, by intra-dermal (i.d.) administration of CD40-targeting agents 
and by relative over-expression of CD40 on DCs, any binding that might occur to other cells doesn’t 
interfere with efficient vaccine delivery to DCs.292, 293 The DC selectivity is also necessary to reduce side 
effects, as agonistic αCD40 antibodies for example were shown to induce polyclonal stimulation of B 
cells leading to splenomegaly in vivo.294, 295 On the other hand, targeting B cells might contribute to 
the vaccine efficiency of αCD40-antigen conjugates.114 In addition, dual targeting of DC surface 
receptors and TLRs, that are both specifically expressed on DCs, may provide further selectivity. Since 
TLR5 is not expressed on B cells but on DCs, the αCD40.FlgCMV/mNPM1 construct might preferentially 
target DCs. 
All MACS were site-specifically coupled to the adjuvant, either by genetic fusion or by an αFITC scFv. 
It was shown that the flagellin fusion to αCD40CMV didn’t interfere with the αCD40 binding site and 
didn’t affect protein integrity. This was an important finding, as other coupling methods might have 
disadvantages. In a similar approach, Kreutz et al. developed an antibody–antigen–adjuvant conjugate 
consisting of an αDec205-specific antibody conjugated via sulfo-SMCC linkers to the model antigen 
ovalbumin (OVA) and CpG oligodeoxynucleotides (ODN). Although they could show the functionality 
of their molecule, they encountered the problem that CpG fusion altered the antibody binding and 
uptake. The fusion allowed the delivery of both antigen and adjuvant to cells partially independently 
of the DC-targeting antibody.134 Also, the covalent linkage via amine-to-sulfhydryl crosslinkers might 
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be too strong to release the TLR agonist in the endosome for optimal interaction with its receptor, 
whereas the FITC-ligated TLR agonist should be released by acidic pH. However, this interaction might 
not be strong enough to be used in a clinically relevant molecule. Coupling the TLR agonist via FITC-
αFITC interaction was mainly an elegant way to test the potency of different FITC-TLR agonists in vitro. 
The genetic fusion variant of flagellin, on the other hand, might be used in a clinical setting. As flagellin 
anyway interacts with a TLR located on the cell surface, an intracellular cleavage is not necessary. 
Moreover, the capacity of genetically fused flagellin to interact with TLR5 could already be validated 
in functional assays. 
The combination of αCD40CMV/mNPM1 and flagellin revealed the most promising results concerning DC 
maturation and T cell response when used in an IgG1 format. TLR5 agonists are favourably positioned 
among other TLR ligands, even if used systemically, because of a restricted expression pattern in 
tissues (primarily in the gut, liver and bladder) and an uniquely safe profile of induced cytokines.190 
Flagellin is not only recognized at the cell surface by TLR5, but also by the cytoplasmic neuronal 
apoptosis inhibitory protein (NAIP) and NLR-containing a CARD domain (NLRC)-4, which activates the 
inflammasome pathway and thereby enhances their effects on innate and antigen-specific cellular 
immunity.296, 297 A derivative of flagellin called entolimod, which is similar to the truncated flagellin 
version used in our molecule, has been initially established as a potential treatment for lethal radiation 
exposure.184, 185 Flagellin was also shown to induce potent anti-viral immune responses in animals and 
in clinical trials, when it was used as a fusion protein with antigens or as a separate adjuvant combined 
with vaccines.186-188, 298, 299 In mouse studies, TLR5 ligation by flagellin was able to convert tolerogenic 
DCs into activating APCs that preferentially induce Th1 responses.300 As flagellin is also reported to 
elicit direct antitumoral effects, a combination with DC vaccines in the cancer setting was a logical 
consequence. 189-191, 301, 302 Data from this work proves that flagellin performs well if combined with a 
DC-targeting antibody-peptide conjugate. Unfortunately, the flagellin fusion drastically decreased the 
expression yield of the αCD40 antibody by around 6-fold. For its application in the clinics, the cell 
system or transfection efficiency would need to be optimized for higher expression levels.  
Since the other tested TLR agonists, LPS and ssRNA40, were indirectly linked to the antibody via an 
αFITC scFv, the fusion did not affect expression yields. LPS has been developed and tested mostly as 
monotherapeutic for the treatment of cancer.303-305 In these trials, toxicities were reported and LPS 
has long been considered too toxic for human use. After the formulation of LPS have been optimized, 
the present GMP grade endotoxin has a stronger safety profile and causes a transient, but well 
tolerated systemic inflammatory response in a dose-dependent manner.306, 307 Further attempts were 
made to replace LPS by detoxified versions. Among those, MPL is particularly attractive as an adjuvant 
for anti-cancer vaccination due to its capacity to induce robust Th1-polarized and cell-mediated 
immunity while reducing toxicity.308 MPL has already been evaluated as a cancer vaccine adjuvant in 
published clinical trials and is the only defined TLR ligand approved as part of a vaccine.178, 179  
The phosphothioate-protected RNA oligonucleotide ssRNA40 from the U5 region of HIV-1 was first 
synthesized by Heil et al. in 2004. It was shown to stimulate DCs and macrophages to secrete 
proinflammatory cytokines by interacting with human TLR8.164 The combination of nucleic acid-based 
TLR agonists, such as ssRNAs, with in vivo DC vaccination approaches appears feasible since their 
cognate TLRs are located in the endosomal compartments. These TLR agonists cannot easily cross 
membranes due to their size and negative net charge.309 If the ssRNA is fused to a DC-targeting 
antibody, it should be specifically internalized together with the antibody into the endosome. 
Presumably, only the DCs that have taken up the antigen become activated leading to a highly cell-
specific immune response. For other vaccination approaches, cationic carrier systems have been 
employed to enable cellular uptake and increase half-life in the circulation.310 Complexing the ssRNA40 
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with PLA acts in a similar way, but unspecific uptake in other cells is commonly observed using these 
techniques that leads to unwanted off-target effects.309 Combining DC-targeting antibodies with 
nucleic acid-based TLR agonists might be also beneficial for reducing side effects. However, our data 
have shown that the uptake of the ssRNA40 into the DC is not efficient, if the RNA is coupled via an 
αFITC scFv. Thus, a high dose of ssRNA40 would be necessary to reach a level of intracellular ssRNA40 
that is sufficient to induce immune responses. This would make it a highly expensive and not clinically 
feasible approach. Alternatively, direct conjugation of ssRNAs or small molecule TLR8 ligands have 
been already applied for peptide-based vaccines and might also be a good strategy for in vivo DC 
vaccination.243, 311, 312  
 
5.4. State of the art and optimization potential  
DC vaccines are in general safe and able to promote antitumor immunity. However, many previous 
attempts to develop effective therapeutic cancer vaccines yielded disappointing results as the 
vaccines produced durable objective clinical responses in only a minority of patients with measurable 
disease.313 This was not only observed for ex vivo DC vaccination approaches that have been vigorously 
investigated in clinical trials for decades, but also for in vivo DC-targeting.69 Most of the clinically used 
antibody-based vaccines include carrier systems such as liposomes, but only two of them are pure 
antibody–peptide conjugates. CDX-1307 and CDX-1401 from Celldex Therapeutics target either MR or 
Dec205 and are tested in phase I or II clinical trials to treat advanced epithelial malignancies.135, 136 
Both are administered together with the TLR agonists poly(I:C) and R848 as adjuvants. No dose-
limiting toxicities were observed, but only a low number of patients responded, mostly only with a 
disease stabilization. Therefore, new vaccine designs are needed to improve the induction of an 
immune response and its durability.  
The key lessons learned from failed vaccine attempts include: the need for multiple, immunogenic 
antigens, the importance of potent vaccine technologies and co-stimulation, and the need to abolish 
tumor-mediated immunosuppression.60  New strategies, such as ligandome analyses or in silico tools 
using high-throughput sequencing data, are enabling the selection and construction of more 
immunogenic TAAs and the identification of tumor-specific neoantigens.60, 314 Targeting multiple 
peptides or long proteins to DCs including both MHC I and II epitopes is presumably beneficial over 
single peptide vaccines. Although CD4+ T cells do not exhibit direct antitumor activity, their presence 
amplifies antitumor immune responses by boosting CD8+ T cells. In addition, CD4+ T cells are major 
players in the transition of the tumor microenvironment towards an antitumor milieu.315 The reversion 
of immunosuppression can also be achieved by combination of DC vaccines with immune checkpoint 
inhibitors (ICIs) and other immunomodulators, which has already shown promising pre-clinical results 
and is currently tested in clinical trials.316, 317 Further, the success of a DC vaccine depends on the 
amount of delivered co-stimulatory signals. A combination of different TLR ligands with potential 
synergistic activity might provide advantages.318 TLR3 and TLR9 agonists exhibited good synergies in 
human DCs as shown by previous studies.319, 320 The clinically approved vaccine adjuvants AS01, AS02 
and AS04 indicate that a combination of one TLR ligand with different adjuvants, such as saponins or 
alum, can be potent and safe to use in the clinic.41 Besides TLR ligation, activating the STING pathway 
is a promising strategy to induce co-stimulation of T cells by DCs. In a recent study, the STING activator 
c-di-AMP elicited superior adjuvant properties than the formulation poly(I:C)/CpG after vaccination 
with soluble protein antigen or Dec205-mediated antigen targeting to DCs.193 Fu et al. have shown in 
pre-clinical models that cancer vaccines formulated with cytosolic cyclic dinucleotides (CDNs) can cure 
established tumors resistant to PD-1 blockade, highlighting again the adjuvant potential of STING 
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agonists.321 For adjuvants directly acting on DCs and for the agents modulating the tumor 
microenvironment, more work needs to be done to determine which combinations are most effective 
and to find out the optimal dose scheduling for each component.60 
A further optimization of in vivo DC vaccines might be achieved by targeting several receptors in a 
vaccination approach. There is still no consensus on which DC receptor would be a choice of priority 
in terms of targeting antigen. In addition, the selected DC receptor determines not only the targeted 
DC subtype but also the intracellular trafficking pathway. This might be important if multipeptide 
vaccines including also MHC II epitopes are investigated, as MHC II predominantly resides in late 
endosomes.32 Thus, targeting multiple receptors instead of a single receptor could give a synergistic 
boost to generate activated T cells.111  
These are general improvements to optimize vaccination approaches, which can be also transferred 
to the MACs developed in this thesis. In addition to the aforementioned points, the MAC activating 
TLR4 could be optimized by exchanging LPS by its detoxified version MPL, if its fusion is possible. 
Ligation of TLR8 could be achieved by covalent coupling of a small molecule TLR8 agonist, such as 
thiol-functionalized 3M-012. This is a closely related analogue of R848 and could be conjugated via 
thiol-maleimide chemistry to amine groups of antibodies.322 A more promising method to couple 
agonists of intracellular TLRs, however, is a pH-sensitive linker that is cleaved in the endosome to 
release the payload.323 This technique, which has been initially developed for their application in 
antibody–drug conjugates, ensures optimal ligand interaction with the intracellular TLR that is not 
sterically hindered by the attached antibody. To activate STING as an alternative PRR pathway, the 
generation of an αCD40 antibody coupled to a chemically modified cGAMP version is already planned 
in collaboration with the chemistry department.  
The most promising and neoantigen-directed molecule αCD40.FlgmNPM1 has still some optimization 
potential. A longer linker between the heavy chain and flagellin might facilitate proper folding and 
secretion thereby possibly increasing the expression yield. The N-terminal fusion of flagellin to an Fc 
domain has been shown to elicit slightly superior activity compared to the C-terminal fusion (data not 
shown). Therefore, fusing flagellin to the N-terminus of the heavy chain might also be a version to be 
tested in the future, even if this comprises the risk of interfering with the CD40-binding site. 
Alternatively, in the C-terminal fusion molecule the D0 and D1 domain could be swapped to mimic the 
naturally occurring terminal position of D0. 
The therapeutic outcomes cannot only be ameliorated by optimizing the antibody-based vaccine itself, 
but also by adapting therapeutic regimens. In particular, different immunotherapeutic approaches 
have the potential to synergize.324 Therefore, the best strategy would be to not to investigate DC 
vaccines as stand-alone drugs, but to combine it with other immunotherapies such as the already 
mentioned ICI. Especially if ICI was used with neoepitope-based vaccines, the repertoire of 
neoantigen-specific T cells was enhanced, which resulted in sustained progression-free survival in 
clinical trials.72, 73 This shows that the combination of DC vaccination with ICIs might overcome the 
anergic state of vaccine-induced T cells.325 In addition, several clinical trials explored the potential of 
post-transfer vaccination to enhance clinical efficacy of adoptively transferred T cells expressing a TCR 
specific for an intracellular tumor antigen.326, 327 In line with this, combining αCD40.FlgmNPM1 with TCR 
gene therapy, in particular with mNPM1CLA-specific T cells generated by Van der Lee et al., could be a 
promising approach to expand transferred T cell in vivo in order to generate a long-lasting response.224  
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5.5. Concluding remarks and future perspectives 
In the present study, MACs were generated to target and activate DCs in vivo. These combined an 
αCD40-DC-targeting domain with the CMV- or mNPM1-specific peptide and the adjuvant in one 
molecule. The coupling of three different TLR agonists as adjuvants was analyzed and compared by 
means of DC maturation and T cell activating potential, but also in respect to molecule design and 
innovation. Fusing flagellin to the Fc-silenced αCD40 IgG1 antibody (αCD40.FlgmNPM1) turned out to be 
the most promising molecule, as it potently increased DC maturation by specifically activating TLR5 
and enhanced the mNPM1-directed T cell response. Thus, we propose αCD40.FlgmNPM1 as a highly 
promising therapeutic approach for AML treatment. We hypothesize that fusing the flagellin domain 
to the antibody leads to decreased side effects and increased clinical efficacy compared to the 
administration of two separate molecules. 
To gain more insights into its mode of action and functionality, αCD40.FlgmNPM1 needs to be further 
investigated. The following experiments need to verify whether the molecule also induce substantial 
expansion of the small pool of mNPM1CLA-specific T cells present in AML patients. This would be a 
prerequisite for the induction of an AML-directed antitumor response in vivo. Finally, the functionality 
of αCD40.FlgmNPM1 needs to be analyzed in a pre-clinical AML mouse model in order to prove whether 
the in vitro results can also be confirmed in vivo and whether the molecule is able to elicit an AML-
directed tumor regression. In vivo studies should also evaluate the potential benefit of αCD40.FlgmNPM1 
in reducing side effects and increasing efficacy compared to the co-administration of the DC-targeting 
antibody and the adjuvant. It would be interesting to explore the efficacy of therapies combining 
αCD40.FlgmNPM1 with ICI or adoptively transferred mNPM1CLA-specific T cells that recognize and kill 
primary AML cells both in vitro and in vivo. 
Collectively, the in vitro evaluation of αCD40.FlgmNPM1 performed in this thesis demonstrated the 
functionality of this novel antibody format and its ability to induce efficient mNPM1-specific T cell 
responses. Thus, the first investigation of neoantigen-delivery to a DC-targeting antibody and of 
mNPM1 as a shared neoantigen in a DC vaccination approach was successful. The positive results 
motivate for further studies and provide the rational for αCD40.FlgmNPM1 to become a future treatment 
option for AML patients. 
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7. List of abbreviations 
 
Acronym Definition 
α Anti- 
ADCC Antibody-dependent cellular cytotoxicity 
ADCP Antibody-dependent cellular phagocytosis 
AICD Activation-induced cell death 
ALR AIM2-like receptors 
AML Acute myeloid leukemia 
APC Antigen-presenting cell 
BCG Bacillus Calmette-Guérin 
BCL-2 B cell lymphoma 2 
BiTE T cell engaging bispecific antibody 
CAR Chimeric antigen receptor 
CARD Caspase activation and recruitment domain 
CD Clusters of differentiation 
CD40L CD40 ligand 
cDC myeloid/conventional DC 
CDC Complement-dependent cytotoxicity 
CH Constant domain of the heavy chain 
cGAS cyclic GMP-AMP synthase 
CL Constant domain of the light chain 
CLR C-type lectin receptor family 
CpG Deoxycytidyl-phosphate-deoxyguanosine 
CPP Cell-penetrating peptide 
CRD Carbohydrate recognition domains 
CTL Cytotoxic T lymphocyte 
CTLA4 Cytotoxic T-lymphocyte antigen 4 
DAI DNA-dependent activator of IFN-regulatory factors 
DAMP Danger-associated molecular pattern 
DC Dendritic cell 
DC-SIGN DC-specific ICAM-3 grabbing non-integrin 
DDX41 DEAD box polypeptide 41 (DDX41) 
Dec205 205 kD membrane protein 
DNA Deoxyribonucleic acid 
DNGR-1 dendritic cell natural killer lectin group receptor-1 
DPBS Dulbecco’s phosphate buffered saline 
E.coli Echerichia coli 
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmatic reticulum 
Fab Antigen-binding fragment 
FACS Fluorescence-activated cell sorting 
FBS Fetal bovine serum 
Fc Fragment crystallizable 
FcR Fc receptors 
FDA U.S. Food and Drug Administration 
FITC Fluorescein isothiocyanate 
Flg Flagellin 
Flt3L Fms-like tyrosine kinase 3 ligand 
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GM-CSF Granulocyte macrophage colony-stimulating factor 
GMP Good manufacturing practice 
GO Gemtuzumab ozogamycin 
HIV Human immunodeficiency virus 
HLA Human leukocyte antigen 
HPV Human papilloma virus 
HSC Hematopoietic stem cell 
i.d. Intradermal 
ICI Immune checkpoint inhibition 
iDC Immature DC 
IDH  Isocitrate dehydrogenase  
IFI16 interferon-γ inducible protein 16 
IFN Interferon  
Ig Immunoglobulin 
Igκ leader Ig kappa leader 
IL Interleukin 
i.t. Intratumoral 
ITAM Immune-receptor tyrosin-based activation motifs 
ITIM Immune-receptor tyrosine based inhibitory motifs 
KD Dissociation constant 
KMT2A Histone-lysine N-methyltransferase 2A 
LAA Leukemia-associated antigen 
LB Lysogeny broth 
LC Langerhans cell 
LPS Lipopolysaccharide 
LRR Leucine-rich-repeat 
LSC Leukemic stem cell 
LSP long synthetic peptides 
m mutated 
mAb Monoclonal antibody 
MAC Multifunctional antibody construct 
M-CSF Macrophage colony-stimulating factor 
mDC Mature DCs 
MDS Myelodisplastic syndrome 
MFI Mean fluorescence intensity 
mFlg Mutated flagellin 
MHC Major histocompatibility complex  
MLL Mixed lineage leukemia 
mNPM1 Mutated nucleophosmin 
moDC Monocyte-derived DC 
MPL Monophosphoryl lipid A 
MR Mannose receptor 
MyD88 Myeloid differentiation factor 88 
NAIP Neuronal apoptosis inhibitory protein 
NF-κB Nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
NK cell Natural killer cell 
NLR Nod-like receptors  
NLRC4 NLR-containing a CARD domain 4 
NPM1 Nucleophosmin 
NY-ESO-1 New York esophageal squamous cell carcinoma-1 
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ODN Oligodeoxynucleotide 
OVA Ovalbumin 
PAMP Pathogen-associated molecular pattern 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
pDC Plasmacytoid dendritic cell 
PGLALA P329G, L234A and L235A mutations 
p-MHC Peptide-MHC complex 
PRAME Preferentially expressed antigen in melanoma 
PRR Pattern recognition receptor 
p-value Probability value 
RLR RIG-I-like receptors 
RNA Ribonucleic acid 
RU Response unit 
scFv Single chain variable fragment 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEC Size exclusion chromatography 
SEM Standard error of the mean 
SMCC Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
ssRNA Single-stranded RNA 
STING Stimulator of interferon genes 
TAA Tumor-associated antigen 
TAP Transporters associated with antigen processing 
TCR T cell receptor 
Th cell T helper cell 
Tm Melting temperature 
TIR Toll/IL-1R homology 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
TRIF TIR domain containing adapter-inducing interferon 
TSA Tumor-specific antigen 
WT1 Wilm’s tumor protein 1 
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